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ABSTRACT  
 
Introduction 
Complications of severe infection or acute trauma include a cascade of 
immunological dysfunctions known as SIRS (Systemic Inflammatory Response 
Syndrome), that affect response to treatment, prolonging and complicating the 
course of illness and jeopardizing clinical outcome. Timing and the nature of 
nutritional support in the Intensive Care Unit (ICU) setting may influence this 
process. Against this background, and despite some trials demonstrating 
beneficial clinical outcomes for the use of immune-modulating diets (IMD), the 
findings of the US summit on immune-enhancing enteral therapy concluded that 
the currently available enteral immune-enhancing formulas are “first-generation 
products” which may not be appropriate in patients with SIRS or severe sepsis. 
This highlights a need for alternative nutritional products that target the specific 
needs of this patient population. As such, Intestamin® is designed for use in 
severely stressed patients as an immune-modulating enteral feed supplement 
which aims to improve maintenance of gut barrier integrity and immune 
response.  
Aim 
The aim of this pilot study was to investigate the effect of Intestamin® 
administration to critically ill patients, and in particular, to determine if 
administration would impact on nosocomial infections, ventilation days and the 
length of stay in the ICU.  
Methods 
The study design was an open label, retrospective case control, analytical study, 
of patients admitted to the ICU in The Bay Hospital, Richards Bay, between 
January 2002 and November 2003, who received Intestamin®. Patients were 
selected for the study from post-surgery and post-trauma patients at high risk of 
sepsis and SIRS, and critically ill patients with manifested SIRS or severe sepsis. 
Development of respiratory and urinary sepsis was used as surrogate markers 
for progression to severe sepsis and SIRS. Additionally, duration of ventilation 
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and ICU stay were considered representative of the response to treatment and 
degree of clinical complications.  
Results 
The findings of the study demonstrated a significant difference in the rates of 
respiratory infection(p=0.05), positive sputum and tracheal aspirate 
cultures(p=0.03) and urinary catheter tip cultures(p=0.04). with statistically lower 
rates in the intervention group compared to the control group. There were no 
significant differences in the rates of urinary tract infection, septicaemia or in 
combined sepsis rates between the two groups. There were statistically 
significant higher rates of positive pus cell counts in the sputum(p=0.003) and 
urine(p=0.01) in the intervention group, compared to the control group. No 
corresponding reduction in ventilation days or ICU stay was observed.  
Conclusion  
In this patient population, early enteral nutrition with specially formulated IMD, 
(Intestamin®), did result in a significant reduction in respiratory infections, but not 
in other types of sepsis, ICU or ventilator days in critically ill ICU patients. This 
positive finding in some, but not all endpoints collected, may reflect  confounding 
factors in the small patient population or the choice of clinical endpoints, rather 
than a genuine limitation in the benefit. IMD remains a tantalizing and 
scientifically plausible intervention in this patient population, with larger clinical 
trials necessary to confirm outcomes. The study supports the safe use of 
Intestamin by the nasojejenal route in this patient population. 
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OPSOMMING 
 
Inleiding 
Komplikasies van erge infeksie of akute trauma sluit ‘n kaskade van 
immunologiese disfunsie in, bekend as SIRS (Sistemiese Inflammatoriese 
Respons Sindroom), wat die respons op behandeling affekteer, die verloop van 
siekte verleng en kompliseer asook die kliniese uitkoms beïnvloed. 
Tydsberekening en die aard van die voedingsondersteuning in die Intensiewe 
Sorg Eenheid (ISE) mag hierdie proses beinvloed. Teen hierdie agtergrond, en 
ten spyte van sommige studies wat die voordelige kliniese uitkoms vir die gebruik 
van immuun-modulerende diete (IMD) toon, het die “US summit” oor immuun-
verbeterde enterale terapie tot die gevolgtrekking gekom dat die huidige 
beskikbare enterale immuun-verbeterde formules, “eerste-generasie” produkte is, 
wat moontlik nie toepaslik is vir pasiente met SIRS of erge sepsis nie. Dit 
beklemtoon ’n behoefte aan  alternatiewe voedingsprodukte wat die spesifieke 
behoeftes van die genoemde pasient populasie teiken. Intestamin® is ontwerp vir 
gebruik in erge gestresde pasiente as ‘n immuun-modulerende enterale 
voedingssupplement doelgerig om spysverteringskanaal integriteit te onderhou 
en immuniteit te verbeter. 
Doel 
Hierdie loodsstudie se doel was om die effek van Intestamin® toediening aan 
kritiek siek pasiente te ondersoek, spesifiek om vas te stel of die toediening 
impakteer op nosokomiale infeksies, ventilasie dae en dae in ISE. 
.Metode 
Die studie ontwerp was ‘n oop, retrospektiewe, geval kontrole, analitiese studie 
van pasiente opgeneem in die ISE van The Bay Hospital, Richardsbaai, tussen 
Januarie 2002 en November 2003, wat Intestamin® ontvang het. Pasiënte is 
geselekteer vir die studie uit post-chirurgies en post-trauma pasiente wat hoë 
risiko was vir sepsis en SIRS, en kritiek siek pasiente wat reeds manifisteer het 
met SIRS of erge sepsis. Ontwikkeling van respiratoriese en urinêre sepsis is 
gebruik as surrogaat merkers vir die progressie na erge sepsis en SIRS. 
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Addisioneel is duur van ventilasie en ISE verblyf beskou as verteenwoordigend 
vir die respons op behandeling en die graad van kliniese komplikasies. 
Resultate 
Die bevindinge van die studie het betekenisvolle verskille aangedui in die 
voorkoms van respiratoriese infeksies(p=0.05), positiewe sputum en trachiale 
aspiraatkulture(p=0.03) en urine kateterpunt-kulture(p=0.04) met statistiese laer 
voorkoms in die intervensie groep in vergelyking met  kontroles. Geen statistiese 
verskille in die voorkoms van urineweg-infeksies, septisemia of in gekombineerde 
sepsis voorkoms tussen die twee groepe is gevind nie. Daar was statistiese 
betekenisvolle hoër voorkoms van etterselle hoeveelhede in die sputum(p=0.030 
en uriene(p=0.01) van die intervensie groep in vergelyking met die kontrole 
groep. Geen ooreenkomstige vermindering in ventilasie dae of ISE verblyf is 
opgemerk nie. 
Gevolgtrekking 
In hierdie pasiënt populasie, het vroeë enterale voeding met spesifieke 
geformuleerde IMD (Intestamin®), ‘n beduidende vermindering in respiratoriese 
infeksies getoon, maar nie in ander tipes sepsis, ISE of ventilasie dae by kritiek 
siek pasiente nie. Hierdie positiewe bevindinge in sommige. maar nie al die 
versamelde eindpunte nie, reflekteer moontlike bydraende faktore in die klein 
pasiënt populasie of die keuse van kliniese eindpunte, eerder as a ware 
beperking in die voordele. IMD bly steeds ‘n uitdagende en wetenskapilik 
uitsonderlike intervensie in hierdie pasiënt populasie, wat groter kliniese studies 
benodig om die uitkoms te bevestig. Die studie ondersteun die veilige gebruik 
van Intestamin® via die nasojejenale roete in kritiek siek pasiënte. 
 
   
vii 
 
DEDICATION 
 
For my late Dad, I finished this because of your belief in me. 
   
viii 
ACKNOWLEDGEMENTS 
 
A special word of thanks to my dear husband who spent hours behind the 
computer to help me design tables, graphs and find lost documents. Henk, thank 
you for supporting me and keeping me going. The staff at Netcare The Bay 
Hospital ICU, thanks for keeping to the study protocol. A special thank you to Dr 
Gunther Kelling and Dr Pieter van Rooyen for always being available to answer 
questions when things did not make sense to me. Thanks to Prof Demetre 
Labadarios (study leader) and Janicke Visser (co-study leader) for their 
encouragement and patience. The laughter and love of family and friends (Coffee 
Club) were invaluable and the understanding of colleagues cannot go 
unmentioned. Last but definitely not least at all, a special thanks to Dr Christine 
Kelbe, who gave this thesis a “heart”, who spent hours listening to questions and 
helped with the interpretation of the data, motivated me when times were tough 
and just kept going despite any hiccoughs. Chris, this paper was like “rolling like 
a ball” to you in Pilates. There are no words to thank you enough. 
 
   
ix 
LIST OF ABBREVIATIONS 
 
APACHE : Acute Physiological Assessment and Chronic Health  
   Evaluation1 
 
ARDS  :  Adult respiratory distress syndrome1 2 
 
CRP  :   C-Reactive protein1 3 
 
EEN   : Early enteral nutriton1 4 
 
EN  :  Enteral nutrition1 4 
 
GALT   :  Gut associated lymphoid tissue 1 5 
 
GSH  :   Glutathione in the reduced, monomeric form 1 6 
 
GSSG  :  Glutathione in the oxidized, dimeric form1 6 
 
GI  :  Gastrointestinal 1 6 
 
ICU   :  Intesive care unit 1 7 
 
IMD  : Immune-modulating diets1 4 
 
LCFA   :  Long chain fatty acids1 8 
 
MODS : Multiple organ dysfunction syndrome1 9 
 
MOF   :  Multiple organ failure1 9 
 
OFR   :  Oxygen free radicals 1 10 
 
SCFA  : Short chain fatty acid 1 10 
 
SIRS  :  Systemic inflammatory response syndrome 1 11 
 
TNF  :  Tumour necrosis factor1 12 
   
x 
LIST OF DEFINITIONS 
 
Control group:   
The group of subjects who did not receive the product Intestamin® 
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CHAPTER 1 : INTRODUCTION AND RESEARCH QUESTION 
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
INTRODUCTION 
The consensus recommendations of the summit on immune-enhancing enteral 
therapy, highlight a need to develop alternative nutritional products which target 
the specific needs of the critically ill. Extrapolating on the results for conventional 
immune enhancing diets in other patient populations, this may constitute an 
additional strategy to positively influence the course of the metabolic and 
immunological dysfunction in critically ill patients.11  
 
In order to understand the scope for nutritional immunomodulation in these 
patients, it is necessary to identify the underlying pathophysiological processes 
which lead to immune dysregulation and SIRS as well as the consequences of 
this response in the body. These processes will be described, with particular 
emphasis on those key systems influenced or modified by the nature and timing 
of the nutritional support provided. 
 
This will be used to highlight the justification for new generation enteral feeds, as 
represented by Intestamin®, over conventional first generation products and the 
reason  Intestamin® was chosen as a nutritional intervention in this study of 
outcome of crtically ill ICU patients. 
 
1.1 THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 
 
SIRS is defined as a systemic inflammatory response to any severe insult, 
both infectious and  noninfectious. These may include conditions such as 
pancreatitis, ischemia, multiple trauma and tissue injury, hemorrhagic shock or 
burns. The use of the term SIRS is independent of the triggering  insult.14  
 
Sepsis is defined as the inflammatory response to infection and is one cause 
of SIRS. Sepsis is therefore a risk factor for SIRS.11 (Figure 1.1)  
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Figure 1.1 The relationship between systemic inflammatory response 
syndrome (SIRS), sepsis, and infection  
(Source: Martindale RG, Sawai R 200714) 
 
Sepsis, severe sepsis, septic shock and SIRS  represent a continuum of 
clinical and pathophysiological severity which is correlated with increasing organ 
dysfunction and mortality.15,16 
 
Multiple organ dysfunction syndrome (MODS) is the term which is applied to 
acutely ill patients with altered organ dysfunction, who are unable to maintain 
metabolic homeostasis.11 
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Figure 1.2  Dynamic process from SIRS and SEPSIS to MODS as defined 
by the 1991 Consensus Conference  (Source: Alberti et al. 2002 15 Matot I, 
Sprung CL 2001 16) 
From Manifestation
SIRS 
multiple trauma 
burns 
pancreatitis 
post major 
surgery 
etc 
From 
SEPSIS 
SIRS Systemic Inflammatory Response Syndrome to severe clinical 
insults 
At least 2 criteria of 
temp. > 38ºC or < 36ºC 
heart rate > 80 beats/min 
respiratory rate > 20 breaths/min. OR 
 PaCO2 < 32 mmHG (< 4,3kPa) 
Criteria as above 
Organ disfunction 
Hypoperfusion and perfusion abnormalities (lactic 
acidosis, oliguria, acute alteration in mental state etc.) 
OR 
Sepsis induced hypotension = a systolic blood pressure 
Criteria as above 
Sepsis induced hypotension despite adequate 
fluid resuscitation 
Mortality ↑ 
Severe SEPSIS Severe SIRS 
Septic Shock 
MODS/Multiple organ dysfunction 
syndrome 
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MODS, analogous to SIRS, represents a continuum of physiological 
derangements. It describes a dynamic process of increasing pathological 
severity.  MODS is a frequent complication of SIRS and may be considered the 
more severe end of the spectrum of SIRS and sepsis. It is viewed as a 
complication of SIRS and sepsis, to be prevented, rather than a disease to be 
treated. MODS may be described as being either primary or secondary 
(Figure.1.3).  
 
Figure 1.3 The different causes and results of primary and secondary 
multiple organ dysfunction syndrome (MODS) 
  (Source: Brun-Buisson C 2000. 17)  
 
Primary MODS results immediately from a primary insult, e.g. pulmonary 
contusion, whereas secondary MODS results rather later from SIRS or sepsis..11 
 
The incidence of SIRS and sepsis is still very high in the ICU setting and 
correlates with a high mortality. The retrospective study by Brun-Buisson 
calculated the prevalence of severe sepsis and shock to be 10-15 % of all ICU 
patients 17 and the recently published prospective cohort study by Alberti et al 15 
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documented a similar prevalence,  with 25% of all patients who stayed longer 
than 24 hours in the ICU developing severe sepsis and/or septic shock. 
 
The 28-day mortality rate for severe sepsis is approximately 20-40% and that for 
septic shock 40-60%. Due to tremendous progress in the initial care of severe 
trauma patients, early mortality has been reduced over the last  years. Late 
mortality, however, is still high and related to the high incidence of SIRS and 
MODS. It is evident, therefore, that there is a need for promising new approaches 
to treat and prevent  SIRS, sepsis and its sequelae.18 
 
Based on the given scientific rationale, Intestamin® may belong to these new 
promising approaches. 
 
1.2 SIRS METABOLISM AND NUTRITIONAL IMPLICATIONS  
The goal of this chapter is to learn why “too many calories and the wrong 
combination of caloric substrates can do more harm than good” during SIRS and 
MODS. The review article by Kim et al19 is the main source for the following 
explanation. 
 
Catabolism is the metabolic response to both stress and hunger, usually referred 
to as hypermetabolism. There is, however, a profound difference in the extent to 
which substrates may be utilized for stress and for hunger. 19 20 
 
As both metabolic situations may occur in the critically ill, it is important to know 
what the differences between stress and hunger metabolism are and also the 
nutritional consequences of these responses. 19 20 
 
During hunger, substrate utilization is not impaired. Substrate utilization adapts to 
nutrient availability. Consequently, increased substrate supply may reverse 
hunger-induced catabolism. During stress, however, substrate utilization is 
impaired. Catabolism, that is the increased mobilization of endogenous energy 
and protein stores, cannot be reversed or stopped but only be reduced by 
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exogenous substrate supply. The overall aim of stress-induced catabolism is to 
use the endogenous fat and protein stores for the adequate provision of energy 
and glucose for glucose dependent tissues such as the brain, erythrocytes and 
immune system, and to release amino acids and nitrogen for the de novo 
synthesis of functional proteins, in particular acute phase proteins involved in the 
immune response. Both hunger and stress precipitate an imbalance between 
insulin and the counter regulatory hormones, in favour of the latter which results 
in catabolism (Figure. 1.4). During stress, unlike hunger metabolism, this 
imbalance is induced despite increased release of insulin, accompanied by a 
much higher increase of the catabolic insulin counter regulatory hormones, such 
as glucagon, cortisol and catecholamines. This is one of the main regulatory 
mechanisms for the difference in substrate utilization during hunger and stress. 
Another difference lies in the increased release of inflammatory mediators during 
stress enhancing catabolism, which is not the case during hunger.19 
 
 
Figure 1.4  Pattern of hormones and inflammatory mediators in stress and 
hunger metabolism 
(Source: Suchner U. 2003. 21)  
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The characteristic features of stress-induced hypermetabolism, as determined by 
the neurological and hormonal responses to stress, are summarized in Figure1.5.  
 
Metabolic Pathways
Hepatic Glyconeogenesis
Lipolysis
Proteolysis
Energy availability
Glucose
Lactate/ Pyruvate
Alanine/ Glutamine
Free fatty acids
Glycerol
Ketones
Enhanced availability of 
endogenous energy
 
 
Figure 1.5 Characteristic features of hypermetabolism – determined by 
the neurological and hormonal response to stress  
(Source: Suchner U. 2003 21) 
 
Stress-induced catabolism cannot be reversed through exogenous substrate 
supply. Nutrition therefore has to be adapted to the actual metabolic situation. 
The primary goal of nutrition during stress metabolism is the maintenance of 
organ and systemic functions, particularly that of the gut, liver, lung and the 
immune system. The goal should be to maintain not to restore lean body mass. 
Under stress conditions nutrition is also termed “metabolic support”.21 22 
 
The amount of energy, fat and carbohydrates which needs to be admnistered to 
a critically ill patient has to be adapted to the actual metabolic capacity for 
substrate utilization and elimination. In practice this can be done through regular 
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control of plasma urea, plasma triglycerides and blood sugar, the regular 
calculation of the urea production rate and the regular determination of the 
respiratory quotient. These help in the recognition of metabolic changes and to 
prevent hyperalimentation, which has been shown to increase morbidity and 
mortality under the conditions of stress metabolism 19 .  
 
The three phases of stress metabolism, as proposed by Cuthbertson, are still 
applicable and very helpful for establishing the prefered nutritional strategy. 
 
The three phases of stress metabolism are phase 1 - the ebb phase, phase 2 - 
the flow phase and phase 3 -the convalescence phase (Figure.1.6) and can be 
described as follows: 
 
 
Figure 1.6 Phases of stress metabolism as defined by Cuthbertson and 
respective nutritional strategies (Source: Cuthbertson DP. 1978. 23) 
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Phase 1 - Ebb phase / shock phase: 
The ebb phase, also known as the shock phase, follows immediately after trauma 
or the onset of severe infections and persists for a few hours, depending on the 
timing of resuscitation, i.e. respiratory support and hemodynamic stabilization of 
the patient. It develops anytime from minutes to approximately 24 hours after the 
insult. The insulin counter-regulatory factors dominate. The stabilization of vital 
functions, respiration, circulation and maintenance of organ functions is a priority. 
Nutrition is not indicated during the ebb phase. 20 23 
 
Phase 2 - Flow phase 
After resuscitation and stabilization of the patient, the flow phase predominates. 
This phase may last for several days or even weeks. The severity of it depends 
on the magnitude of injury and SIRS. Nutrition during this phase should focus on 
metabolic support and maintenance of organs and should therefore be carefully 
planned. 20 23 
 
Phase 3 - Convalescence phase 
The convalescence phase is only achieved after the stress-inducing causes have 
been cured. Only then will the anabolic insulin predominate over counter-
regulatory factors. Positive energy and nitrogen balance can be achieved by 
providing adequate nutrition in order to gain lean body mass.20 23 
 
The three phases do not necessarily follow each other. If stress inducing factors 
reappear  or SIRS develops, the patient may fall back to the flow or even ebb 
phase. This may occur repeatedly and of course needs adaptation of the 
nutritional strategy to the respective metabolic situation.23  
 
To better understand nutritional targets and interventions in these critically ill 
patients and to develop nutritional strategies which are expected to have a 
positive effect on the course of the illness, it is necessary to look more carefully 
at the ebb and flow phases and how these determine the metabolic 
immunological consequences and hence the course of the illness. 
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1.3 THE METABOLIC RESPONSE TO STRESS AND THE INTESTINAL 
DEFENSE SYSTEMS 
 
1.3.1 Metabolic  Response to Stress 
The acute phase response to stress is probably designed to provide energy and 
substrates for protein synthesis and cell replication in visceral tissues ( i.e. liver, 
gut, immune cells and wound tissue) However during prolonged, intense stress, a 
severe depletion of body stores may adversely affect the morbidity and mortality 
of patients and delay the recovery from illness. 20 23 
 
Critically ill patients experience a number of alterations in carbohydrate, lipid, 
amino-acid and protein metabolism (Figure 1.7 – 1.9). Hyperlgyceamia during 
critical illness is caused by increased liver production of glucose and decreased 
glucose utilization in the skeletal muscles and the adipose tissue. The immune 
system, wound tissue, lung and skeletal muscles’ accelerated pyruvate 
production is the result of an increased rate of glycolysis. The liver uses lactate, 
alanine and glycerol, derived from an accelerated lipolysis, as substrates for 
gluconeogenesis. Hypoxia or tissue hypoperfusion further accelerates lactate 
production (Figure 1.7). 10  
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Figure 1.7: Changes in glucose metabolism during critical illness 
(Source: Heyland DK et al. 2006. 10)  
 
When nutritional support is insufficient for energy supply during critical illness, the 
endogenous lipids represent the main source of energy. In the adipose tissue, 
triglycerides (TGs) are hydrolysed to release free fatty acids (FFAs) and glycerol 
into the bloodstream. These increased FFAs result in depletion of intracellular 
TGs stores. Oxidation of FFAs in the peripheral tissue produces energy. The liver 
converts FFAs to ketones or re-estestrifies FFAs to TGs which are released  into 
the bloodstream as very low density lipoprotein (VLDL). Plasma FFA levels 
increase proportionately to the severity of the injury. (figure 1.8). 10   
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Figure 1.8 Lipid metabolism changes during critical illness 
(Source: Heyland DK et al. 2006.  10) 
 
Increased protein breakdown results in muscle mass loss. Glutamine is produced 
in the skeletal muscle which serves as a reservoir of free amino acids. Critically ill 
patients are characterized by a severe depletion of the intramuscular glutamine 
pool and an increased glutamine requirement in the gut, liver, kidney, immune 
system and wound tissue where glutamine is utilized as a major fuel for rapidly 
dividing cells. Glutamine also serves as a precursor for gluconeogesis, nucleotide 
synthesis, ammonia excretion and glutathione formation. An increased rate of 
protein synthesis in visceral tissues partially compensates for the protein 
breakdown from skeletal muscle. The liver oxidizes excess amino acids and the 
muscle oxidizes the excess branched chain amino acids which the kidneys 
excrete as nitrogen. (figure 1.9) Muscle wasting leads to catabolism of the 
diaphragm, intercostal muscles, and heart, with increased risk of pulmonary 
complications from ineffective clearing of secretions. 10  
 
 
Adipose Tissue 
↑ triglyceride hydrolysis 
↑ glycerol and fatty acid 
release 
↓ fatty acid re-esterification 
Liver 
↓ fatty acid re-esterification 
↓ VLDL synthesis 
↓ gluconeogenesis from 
glycerol 
Peripherial tissues 
↑ fatty acid re-esterification 
↓ VLDL synthesis 
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Figure 1.9 Protein and amino acid metabolism changes during critical 
illness. (BCAA – Branched chain amino acids) 
(Source: Heyland DK et al. 2006. 10)    
 
These changes lead to increased energy requirement and protein catabolism and 
contribute to alterations in the immune system and gastrointestinal tract. 
 
1.3.2 Intestinal Defense Systems 
Beyond its digestive and absorptive capacities, the gastrointestinal tract is 
recognized for its immunological role and barrier function. Several studies have 
indicated that “bowel rest” ( when no enteral nutrition enters the digestive tract for 
a period of time) is associated with disruption of the mucosal barrier structure and 
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function, augmenting the inflammatory response to illness and resulting in greater 
infectious morbidity. Awareness of these associations and observations has led 
to the practice of providing early nutritional support to critically ill patients 8 24  
 
1.3.3 The Gastrointestinal Tract a Defense System  
The gastrointestinal tract is usually considered as the organ for nutrient intake, 
nutrient digestion and absorption.There is, however, another extremely important 
role of the gastrointestinal tract which is its role in the overall host defense. 
(figure 1.10)12 23 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Components of Intestinal Defense 
(Source: Vendemiale G et al. 1999 12) 
 
1.3.3.1  Extrinsic defense  mechanisms  
In principle, all extrinsic mechanisms limit the number of antigens (pathogens), 
which may reach the mucosal surface, thus reducing the risk for invasion of the 
intestinal epithelium. These consist of luminal and epithelial surface defense 
mechanisms. 30  
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Intestinal transit time is enhanced by peristalsis, limiting pathogen contact with 
the intestinal epithelium and subsequently possible pathogen adherence by 
preventing stasis in the gut.  
 
The mucous coat is composed of mucin, a highly viscous glycoprotein that 
contains enzymes for digestion as well as IgA for bacterial neutralization. Mucin 
also carries many innate microbial defenses such as lactoferrin, defensins, 
perioxidases, and other potent low molecular weight antimicrobial inhibitors. 
When mucus is released into the gastrointestinal lumen the mucus stream draws 
micro-organisms away from the epithelial cells. In addition its viscous nature 
prevents adherence of micro-organisms to the intestinal epithelium.,26 
 
The physiological intestinal microflora protect against pathogenic bacteria by  
adhering to the intestinal epithelium, reducing the surface area for adherence of 
pathogenic bacteria and  producing antimicrobial substances, such as fatty acids, 
and stimulating epithelial cell growth., 26 
 
IgA is the main immunological component of the extrinsic intestinal defense 
mechanisms. IgA is transported from the underlying gut-associated lymphoid 
tissue (GALT) into the intestinal lumen. It prevents invasion of pathogens by 
trapping micro-organisms, derived from the environment and food, in the mucous 
coat through formation of antigen-antibody complexes. 26 
 
1.3.3.2 Intrinsic defense mechanisms 
Pathogens that successfully escape the extrinsic defense mechanisms are 
confronted with the intrinsic defense barriers consisting of the mucosal epithelium 
and the GALT. 
  
The mucosal epithelium provides various defense mechanisms. Tight junctions 
firmly connect the epithelial cells together, providing an effective mechanical 
barrier to pathogens.  
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Specialized epithelial cells produce mucus, antimicrobial substances or peptide 
hormones which contribute to the extrinsic surface defenses and intestinal 
immune response. 23 26 56  
 
GALT is the umbrella term for all lymphoid tissues located in the intestine, and 
the GALT lymphoid cells account for the estimated 80% of all immunoglobulin- 
producing cells of the body, which quantitatively underlines the importance of the 
gut for the overall immune response.  
 
The GALT is composed of several unique immunological structures (Table 1). It 
plays an important role in the antigen specific immune response for the uptake 
and processing of antigens (pathogens) and the secretion of antibodies, in 
particular the IgA Error! Bookmark not defined. 25 
 
Table 1.1 Immunological structures of the GALT 
 
The Peyer’s Patches are the site where the antigen specific immune response is 
initiated. After a complex process of cell maturation, lymphocytes are primed to 
become either IgA secreting plasma cells or to produce cytokines regulating the 
IgA secretion from the plasma cells. 5 26 27  
 
This summary of intestinal defense demonstrates the major role the gut plays in 
the overall host defense of the body. Disintegration of the intestinal barrier under 
pathological conditions, as is the case in critical illness, will clearly have 
deleterious effects. Thus it becomes obvious that every effort should be made to 
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prevent the breakdown of the intestinal defense barriers in critical illness. To 
guarantee this adequate nutrition route and type of nutrition is of the utmost 
importance. 
 
1.4  THE GASTROINTESTINAL TRACT IN CRITICAL ILLNESS  
 
It is generally assumed that gut dysfunction occurs early in shock, sepsis and 
following trauma and that gut failure and mucosal injury is an unfavourable 
prognostic factor in critically ill patients.28  
 
The following changes are all seen to a variable extent as part of gut dysfunction: 
 mucosal injury 
 increased intestinal permeability 
 disturbed immune functions of the GALT 
 bacterial overgrowth 
 motility disorders 
 ileus 
 malabsorption 
 
1.4.1  Mucosal Injury 
The role of the “canary of the body”, has been attributed to the gut, which means 
that it is a sentinel organ that is particularly susceptible to the interruption of 
blood flow or oxygen and substrate supply. 9.20  
 
Mucosal injury results in increased intestinal permeability and/or the release of 
inflammatory or other toxic substances from the damaged mucosa. 29  
 
The function of the gut as a barrier can weaken after mucosal injury due to 
ischaemia and reperfusion injury. (figure 1.11) 20  
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Figure 1.11 Mechanisms causing mucosal injury during critical illness  
(Source: Heyland DK, Samis A. 2003 29) 
 
1.4.2 Bacterial Overgrowth 
A further problem in critically ill patients is the colonization of the upper 
gastrointestinal tract with bacteria and/or fungi otherwise known as “bacterial 
overgrowth”. Not only the localization, but also the composition of the flora is 
frequently changed during critical illness  (Figure 1.12).  
 
Figure 1.12 Main reasons for bacterial overgrowth in critically ill patients  
(Source: HeylandDK, Samis A. 2003 29) 
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Colonisation of the upper GIT occurs with the same species that cause 
nosocomial infections. Descriptive studies have shown that bacterial overgrowth 
is a risk factor for ICU-acquired infection by either aspiration or translocation. 30 31 
1.4.3 Motility Disorders 
Adequate gastrointestinal motility is essential for proper transport, digestion and 
absorption of nutrients. Motility disorders are a limiting factor for the delivery and 
success of enteral nutrition.32 
 
In the critically ill patient, gastrointestinal motility is often impaired due to multiple 
factors as shown in Table 1.2. 33 
 
Table 1.2 Factors which may disturb gastrointestinal motility in critical 
illness 
Factors For Example 
• Underlying diseases / 
insults: 
Head injury, Burns, Extensive abdominal surgery / 
trauma, Pancreatitis, Diabetes mellitus, Intestinal 
pseudo-obstruction 
• Metabolic 
abnormalities 
Hyperglycemia, Hypopotassemia 
• Drugs Opiates,(mechanical venatilation), Erythromycin, 
Anticholinergics 
• Stress Pain, Sepsis 
• Ischaemia  
• Excessive NO  
 
 
Slow gastric emptying is most common in critically ill patients. The prevalence 
can be up to 80% in these patients. Abnormal gastric emptying is the most 
important consequence of intolerance to naso-gastric delivery of food. Common 
symptoms are abdominal pain, bloating, nausea and vomiting which may result in 
aspiration pneumonia  33  
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In 20% of critically ill patients small intestinal motor dysfunction also occurs, as 
critically ill patients commonly develop abdominal cramps and diarrhoea with 
duodenally delivered  feeds. 33  The incidence of intolerance to early jejunal 
feeding ranges from 13% to 37%. 34 Tournadre et al  have found small intestinal 
motility disorders in 100% of patients after major abdominal surgery. Duodenal 
and jejunal motor activity occured within 2 hours of surgery, but with a higher 
frequency and abnormal migration compared to healthy subjects. When nutrients 
were infused into the duodenum, the motility pattern was not normalized.33  
 
Postoperative ileus occurs to some degree after any abdominal surgery but also 
after several extra-abdominal operations. Ileus is defined as an inhibition of the 
propulsive intestinal motility. 13  
 
The possible consequences of gastrointestinal motility disorders are shown in 
(Figure 1.13). 
 
Absorptive impairment 
-nutrients 
-drugs, water & electrolytes 
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Figure 1.13 Consequences of GI motility disorders in critically ill patients  
(Source: Salloum RH et al. 1991  34 )    
 
Motility disorders in critically ill patients are difficult to rectify. Delayed gastric 
emptying can be overcome by administering enteral feeds into the small intestine 
(nasojejunal feeding)  and/or the administration of propulsive drugs. 34 34 
 
1.4.5 Malabsorption 
The intestinal uptake of certain amino acids and sugars seems to be lower in 
septic patients.34 35 With regard to glutamine, it seems that regulation by 
hormones ensures the uptake of this very important fuel for the intestinal 
mucosa.36 Lipid absorption is severely decreased after trauma, hemorrhage and 
resuscitation. 36 
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Diarrhea 
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-water & 
electrolyte loss 
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Multiple factors contribute to the malabsorbtion of enterally administered nutrients 
in the critically ill patients for example: 
 
 Hypoperfusion of the mucosa 
 Mucosal injury 
 Bacterial overgrowth 
 Motility disorders 
 Drugs 
 Impaired excocrine pancreatic functions. 37 38 
 
1.4.6 The Gut as the Starter and/ or Motor of Multiple Organ Failure (MOF) 
Infection is the most common cause of mortality and morbidity in critically ill 
patients.45 It has been suggested that the gut is involved in the pathogenesis of 
many nosocomial infections and possibly SIRS and MOF. However, the exact 
mechanisms and the correlation between gut failure and MOF remain elusive. 9 It 
has been hypothesized that gut failure is a key factor in the development of late 
(secondary) MOF in critically ill patients after polytrauma and shock. Above all, 
the loss of the very important immunological and mechanical barrier function 
seems to be correlated with the development of systemic infection and 
inflammation. (Figure 1.14). 9 
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Figure 1.14 Hypothesized role of the gut in post-injury MOF  
(Source: Moore FA. 2000 39) 
 
It is assumed that the gut may be an entry point for infectious bacteria and toxins 
into the blood, a phenomenon which is called “bacterial translocation”. The 
bacteria and toxins which have migrated through the gut mucosa reach other 
organs like the liver and the lung via blood and lymph. Stress hormones, free 
radicals and inflammation-promoting mediators like cytokines are released as a 
reaction to the invasion by pathogens. A regular cascade of inflammatory 
processes may result in hyperinflammation, severe organ malfunction and failure. 
(Figure 1.15). 4 39 
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Figure 1.15 Hypothesized role of the gut and liver in the development of 
MOF (Source: Nieuwenhuijzen GA, Goris JA. 1999 40) 
 
There is a great deal of laboratory data identifying bacterial or endotoxin 
translocation as a key factor in sepsis and SIRS. Although clinical evidence is 
outstanding, it is generally believed that bacterial translocation also occurs in 
critically ill patients and was demonstrated in a study in burn patients. 41,42 43,44  
 
Approaches designed to diminish gut permeability early in critically ill patients 
may improve clinical outcome and survival in these patients. 45 
 
1.5 DEPLETION OF KEY NUTRIENTS  
 
1.5.1 Oxidative Stress 
Oxygen is often referred to as a “double-edged sword”. Although it is absolutely 
critical to life, many essential intracellular reactions, for which it is required, result 
in the formation of oxygen free radicals (OFR). OFRs, superoxide radical, 
hydrogen peroxide, nitric oxide and hydroxyl radical, are molecules which have 
one or two unpaired electrons, making them extremely unstable, highly reactive 
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and thus potentially toxic to cell membranes, proteins, and deoxyribonucleic acid 
(DNA).46 (Figure 1.16). 
 
 
Figure 1.16 Clinically relevant free radicals 
(Source: Jacob RA, Burri BJ. 1996 46) 
 
Under normal circumstances, our body is protected against this oxidative 
challenge by natural defense systems such as radical scavenging enzymes or 
vitamins.47 When the balance (Figure 1.17) between these protective antioxidant 
mechanisms and the generation of OFRs is disturbed, we encounter a situation 
called “oxidative stress”. 48 In critical illness, there is an imbalance of increased 
OFR production (during ischemia/reperfusion, inflammation and/or infection) and 
diminished OFR elimination because of a depletion of endogenous antioxidants. 
This may be compounded by pre-existing factors such as age, smoking, 
malnutrition as well as chronic diseases, such as atherosclerosis, diabetes 
mellitus or rheumathoid arthritis. These conditions are all associated with an 
increased production of OFRs or decreased antioxidant capacity or both. 
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Figure 1.17 Imbalance of oxygen free radical production and elimination in 
critical illness 
(Source: Garvin CG, Brown RO. 2001 42)  
 
1.5.2 Development of oxidative stress in critical illness 
 
Oxidative stress plays a major role in the pathophysiological processes 
(ischemia/reperfusion injury, inflammation, infection) induced by critical illness 
Various mechanisms contribute to this association. 47 
 
1.5.2.1 Ischemia/reperfusion injury 
Tissue ischemia, hypoperfusion followed by reperfusion, represents a major 
mechanism by which OFRs are generated in critical illness. The intestinal 
mucosa are some of the most sensitive tissues to ischemia 47 
 
When oxygen availability is limited in the tissue of vital organs by hypoperfusion, 
the cells shift from aerobic to anaerobic metabolism. 
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When cells cannot maintain adequate energy production, they compensate for 
this by breaking down existing ATP. Consequently an influx of Ca2+ ions into the 
cells becomes possible. Increased intracellular calcium activates different 
enzymes, all of which may destroy structural cell components. Under conditions 
of ischemia the enzyme, xanthine oxidase, is activated. (figure 1.18). 43 
 
Reperfusion means the restoration of normal blood flow in tissues and organs. 
Early on during reperfusion of ischemic tissue, a great number of OFRs are 
generated mainly by the activity of xanthine oxidase in the cells.  
 
One of these OFRs, the hydroxyl radical, is especially toxic as it is the most 
reactive OFR. This hydroxyl radical is so reactive that it attacks all biological 
substances such as proteins, polysaccharides, nucleic acids (resulting in DNA 
strand breakage) and polyunsaturated fatty acids . 52 
 
 
Figure 1.18 Important pathophysiological mechanisms by which ischemia 
and reperfusion lead to OFR release and cellular damage 
(Source: Barber DA, Harris SR 1994  52) 
 
Formation of  
xanthine 
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1.5.2.2 inflammatory response to oxidative stress 
The inflammatory response to criticial illness involves the activation of leukocytes 
and other inflammatory cells, leading to a production of reactive oxygen species. 
These species can damage most cellular structures including DNA, proteins and 
lipids, and can become harmful to the patient when the endogenous antioxidant 
defense mechanisms are overwhelmed.49   
 
It is therefore  hypothesized that ischemia/reperfusion after surgery, severe 
trauma or infection produces OFR-driven tissue injury and induces an 
inflammatory response in other, remote organs and tissues. 
 
Inflammation itself stimulates the generation of OFRs and creates a vicious cycle.  
52 
 
 
1.5.3 Antioxidant Mechanisms 
Our organism maintains a complex endogenous defense system against OFRs. 
As a matter of fact, a variety of extra and intracellular antioxidant defense 
systems work together, involving the following components: 
 
 Antioxidant enzymes, i.e. superoxide dismutase, catalase, glutathione 
peroxidase and glutathione reductase 
 Sulfhydryl group donors, i.e. glutathione 
 Antioxidant vitamins E, C, ß-carotene 
 
The first line of intracellular defense consists of a group of antioxidant enzymes. 
When these enzymatic antioxidants are overwhelmed, OFRs are free to react 
with susceptible target molecules within the cell, like fatty acids in the cell 
membrane. The second line of defense is the scavenging of OFRs by non-
enzymatic antioxidants which are water soluble, such as glutathione and vitamin 
C, or lipid soluble such as vitamin E and ß-carotene. 50 
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1.5.3.1 Antioxidant enzymes 
Enzymes directly involved in the intracellular detoxification of OFRs are 
superoxide dismutase, catalase, and glutathione peroxidases 51. Indirect 
antioxidant functions are also mediated by enzymes such as glutathione 
reductase, which restores endogenous antioxidant levels as shown in  
Figure .1.19. 52 
 
 
Figure 1.19 Enzymatic elimination of oxygen free radicals  
(Source: Barber DA, Harris SR 1994 52) 
 
The trace minerals selenium and zinc are also essential cofactors for some of the 
antioxidant enzymes. 
 
Selenium: Selenium is a component of a family of about 35 selenoproteins, 
some of which have important enzymatic functions. Important selenium- 
dependent enzymes include the family of glutathione peroxidases, which reduce 
hydrogen peroxide to water and convert lipid and phospholipid hydroperoxides to 
harmless alcohols, and thioredoxin reductase which helps to control the cellular 
redox status. 7  
 
Zinc:   
Zinc is present in the Cu-Zn form of superoxide dismutase  7  
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1.5.3.2 Sulfhydryl group donors 
Glutathione: 
Glutathione is a tripeptide consisting of the three amino acids glutamine, cysteine 
and glycine. Glutathione is predominantly synthesized in the liver from where it 
can be exported to other organs. Recent information suggests that glutathione 
can also be synthesized in a number of other tissues.  
 
The glutathione synthesis depends on the availability of the precursors 
glutamine, cysteine and glycine. Intracellularly, glutathione is quantitatively the 
most important endogenous antioxidant and radical scavenger. Glutathione is 
present mainly in the reduced, monomeric form (GSH) and, at far lower 
concentrations, in the oxidized, dimeric form (GSSG).  
 
The ratio of GSH to GSSG is the most important regulator of the redox potential 
in the cells. This GSH redox status is critical for various biological events 
including gene activation, regulation of cell proliferation, apoptosis and 
inflammation. (figure 1.20).  
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Figure 1.20 Redox-regulated activation of NF β as a presentation of the 
formation of pro-inflammatory mediators  
(Source: Roth E et al. 2002 53) 
 
It  also has antioxidant activity by reacting with the extremely destructive hydroxyl 
radical  that attacks all cellular components. 53 
 
Vitamin Antioxidants 
 
Vitamin C: Ascorbic acid is the predominant water-soluble antioxidant in the 
 body. Vitamin C has two primary antioxidant functions: First vitamin C reacts 
with and inactivates OFRs in the water-soluble compartments of the body, the 
cytosol, plasma, and extracellular space. Secondly and perhaps equally 
important, vitamin C regenerates oxidized vitamin E..52 
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Vitamin E: Vitamin E is a mixture of closely related compounds called 
tocopherols and ∝-tocopherol is the most potent. Vitamin E is highly lipid soluble 
and is therefore distributed primarily in cell membranes and lipoproteins  where it 
acts to interrupt free radical chain reactions such as lipid peroxidation. By 
reacting with free radicals, a non-reactive Vitamin E radical is formed. This 
“spent” form of vitamin E is then reactivated to its original state by interaction with 
vitamin C and glutathione. 52 
 
Beta-carotene: ß-carotene is a pigment found in all plants and is the major 
precursor of vitamin A. Like ∝-tocopherol, ß-carotene is a lipid soluble substance. 
ß-carotene is a very effective quencher of singlet oxygen and also inhibits lipid 
peroxidation. Interestingly, it seems to be especially effective under low oxygen 
tension (ischemia). 52 
 
The interactions of vitamin C, E, selenium and glutathione are very important in 
order to maintain the antioxidant defenses in the body. All of these antioxidants 
act synergistically. (Figure 1.21) The tocopherol radical reacts with vitamin C to 
regenerate vitamin E. The vitamin C radical is then enzymatically reduced back 
to vitamin C via the selenium-dependent glutathione peroxidase. H2O2 is 
converted to water at the same time. The oxidised glutathione (GSSG) is reduced 
to GSH in the presence of NADPH.  
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Figure 1.21 Interactions of vitamins E and C, selenium and glutathione to 
maintain antioxidant defenses  
(Source: Johnson CD, Kudsk KA. 1999) 
 
It appears that the best antioxidant defense against OFRs and their inflammatory 
consequences involves synergistic efforts of all intra- and extracellular 
antioxidants available in our body. 
 
1.5.4 Antioxidant Depletion In Critical Illness 
Oxidative stress plays a major role in the pathophysiological processes 
(ischaemia/reperfusion injury, inflammation, infection) induced by critical illness 
leading to a high consumption of antioxidants 50. 
 
Hypermetabolism associated with injury and inflammation (infection) is inevitably 
linked with an increased demand for nutrients including the antioxidant vitamins 
and trace elements. 54 
 
Critically ill patients are likely to lose substantial amounts of antioxidant 
micronutrients. Losses may be considerable after burns (since burns exudate 
fluid), in patients with large blood loss (haemorrhagic shock), in those who 
require renal replacement therapy such as hemodialysis or hemofiltration 
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following acute renal failure and in patients with postoperative complications 
leading to gastric aspirate or intestinal fistula losses. 55 
 
Additionally, pre-existing factors can contribute to the oxidative stress and 
consequently the depletion of antioxidants in critically ill patients. Last but not 
least, the adequate nutrient supply is often delayed or interrupted in critically ill 
patients.56 
 
Table 1.3 summarizes the factors which contribute to a depletion of antioxidants 
in critically ill patients. 
 
Table 1.3 Predisposing factors for depletion of antioxidants in critically 
ill patients 
 
Pre-excisting deficiencies: 
- due to old age, smoking, malnutrition, chronic diseases 
Increased requirements: 
- high antioxidant consumption from high radical formation 
- high demands from hypermetabolism 
Increased losses: 
- skin exudate in burns, blood losses, dialysis, gastric aspirate, intestinal fistula 
Reduced supply: 
- post-traumatic , postoperative delay of adequate nutrition/ antioxidant supply 
- interruptions in nutrient supply because of clinical/diagnostic procedures 
 
Many studies have demonstrated low plasma and intracellular concentrations of 
the various antioxidants in critically ill patients. The antioxidant levels in critically 
ill patients decrease rapidly after the insult, trauma or surgery and stay below 
normal levels for several days or even weeks.  
 
In one study, in patients with SIRS, plasma levels of ∝-tocopherol, ß-carotene, 
ascorbate and selenium were significantly lower compared to a (healthy) control 
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group even on the day of admission. Normal levels were not reached during 6 
days in spite of a parenteral supply of antioxidant micronutrients (average daily 
doses: 9.1 mg vitamin E, 100-500mg vitamin C, 120 µg selenium). The levels 
remained severely depressed for ß-carotene which was not included in the TPN. 
The plasma levels of lipid peroxidation products, as a marker of massive 
oxidative stress, increased significantly at the same time 2  . In another study the 
plasma antioxidant potential in patients with severe sepsis was initially decreased 
(< 18 hours) and failed to return to normal before day 6. Continuously low levels 
(up to day 12) of ∝- tocopherol and ß-carotene were strongly associated with a 
higher mortality rate 57.   Berger et al58  measured serum selenium levels below 
normal for up to 20 days in burn patients. Glutathione peroxidase was also 
depressed for 20 days, indicating a deficiency state in these patients. Selenium 
levels remained depressed for more than two weeks in patients with SIRS. 80 59 
 
In severely ill patients with SIRS and sepsis, a significant negative correlation 
was found at the time of admission between plasma selenium concentration and 
APACHE II score (which is an indicator for the severity of the illness).. In sepsis 
patients, mean plasma selenium concentration was negatively correlated with the 
severity of sepsis. 60 
 
Bertin-Maghit et al (2000) evaluated the time frame of oxidative stress in burn 
patients. They found an immediate decrease in plasma levels of antioxidant 
vitamins and trace elements, as well as diminished antioxidant enzyme activities 
on day 1. There was a significant  increase in end-products of lipid peroxidation 
at the same time. This oxidative stress appeared to be sustained, lasting at least 
for the whole observation period of 5 days in this study.61 The inadequate 
availability of antioxidant vitamins and trace elements, in a phase of 
overwhelming production of toxic free radicals, severely enhances oxidative 
stress in critically ill patients. The oxidative damage to cells and tissues and an 
increase in the production of pro-inflammatory cytokines are the consequences. 
The consequent dramatic imbalance of pro- and antioxidants plays a role in the 
pathogenesis of multiple organ dysfunction. 
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Furthermore the deficiency of vitamins and trace elements can impair the 
immune functions with increased likelihood of infectious complications in these 
patients 5 Thus, injury and inflammation cause significant decreases in serum 
antioxidants and antioxidant potential, to counteract oxidative stress in critically ill 
patients immediately after trauma or surgery.  
 
The sicker the patient is, the larger the depletion of antioxidants. Very early 
provision of antioxidant micronutrients (within the first 24 hours) may thus be 
beneficial in highly stressed patients.62  
 
1.5.5 Antioxidant Replacement 
The question arises, how much antioxidant replacement or supplementation 
should critically ill patients receive? 
 
Because of the factors which are dependent on many individual conditions 
(nutritional status of the patient, underlying disease, cause and kind of critical 
illness), it is impossible to predict the exact requirement of antioxidants for an 
individual patient. The amounts of antioxidant vitamins and trace elements in 
common TPN or TEN solutions, for critically ill patients, probably meet the 
minimum dietary recommendations for preventing deficiency. However, in terms 
of meeting the higher demands in these patients, the use of supplemental 
therapeutic concentrations of antioxidants is likely to be required 63 .However the 
optimal therapeutic doses of antioxidant therapies for critically ill patients are still 
unknown. 47 
 
Neither official authorities nor nutrition societies have established 
recommendations for the antioxidant supply to critically ill patients to date. Only a 
few quantitative recommendations have been suggested in the literature (Table 
1.4). 
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Table 1.4 Recommendations for the antioxidant supplementation of 
critically ill patients from current literature 
Per Day Galban 
Rodriquez 
(2000)** 
Berger & 
Shenkin (2000)* 
Borhani & Helton 
(2000)** 
Vit A 3.3 mg 
(better in β-carotene 
form) 
1-2 mg  
Vit E 364 – 910 mg 10 200 mg 910 mg 
Vit C 2000 mg 250 -> 1000mg > 1000mg 
Selenium 100µg 100 – 500 µg  
Zinc 50 mg 10 – 40 mg  
 
*  recommendations for parenteral supply 
**  no recommendations for route of administration 
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Tabel 1.5 Changes of key antioxidant parameters in critical illness 
Critical Illness Antioxidant Parameter Effect References 
ARDS 
Adult Respiratory 
Distress syndrome 
Vit E 
β-carotene 
Vit C 
Selenium 
↓ 
Cross et al. 1990 
Richard et al. 1990 
Nakae et al. 1995 
Metnitz et al. 1999 
Sepsis and septic shock Antioxidant potential 
Vit E 
β-carotene 
Selenium 
Glutathione 
Glutathione peroxidase 
activity 
↓ 
Ogilvie et al. 1995 
Goode et al 1995 
Cowley et al 1996 
Lyons et al 2001 
Burns Vit E 
β-carotene 
Vit C 
Selenium 
Zinc 
↓ 
Berger et al. 1992 
Gosling et al. 1995 
Rock et al. 1997 
SIRS Vit E 
β-carotene 
Selenium 
↓ 
Hawker et al. 1990 
Forcevill et al. 1991 
Curran et al. 2000 
Trauma Vit E 
β-carotene 
Selenium 
Zinc 
↓ 
Berger et al. 1992 
Young et al. 1998 
Weiss et al. 1998 
Acute Renal Failure Selenium ↓ Makropoulos et al. 1997 
Mixed ICU Vit E 
Vit C ↓ 
Takedo et al. 1984 
Schorah et al. 1996 
Barelli et al. 1996 
Kharb et al. 1999 
 
 
 
1.5.5.1 What doses of antioxidants supplementation are safe in 
critically ill patients?  
 
In 2000, the US Food and Nutrition Board of the Institute of Medicine defined and 
then revised (in 2002), tolerable upper intake levels (UL) of antioxidant 
supplements, which are considered the highest daily nutrient intakes that are 
unlikely to pose a risk of adverse health effects for almost all individuals in the 
general population (Table 1.6). 
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The UL was based on a no-observed-adverse-effect level (NOAEL), which is the 
highest intake of a nutrient, at which no adverse effects have been observed, in 
humans. If no other unknown factors are present for a more sensitive group of 
persons, the UL has the same value as the NOAEL. This is the case for vitamin 
C and zinc (table 1.6). 64 
 
Table 1.6 Tolerable upper intake levels (UL) and No observed adverse 
effect levels (NOAEL) of antioxidants . 64 
 
1.6 EARLY ENTERAL NUTRITION IN THE CRITICALLY ILL 
 
In the critically ill, nutritional support may be enteral or parenteral or a 
combination of the two. Partenteral administration may be a convenient approach 
in critically ill, ventilated patients, but it is recognised that enterally administered 
nutrition has additional advantages in preserving the gut in this patient 
population. Early enteral nutrition (EEN) seems to be a particularly important and 
most effective tool to maintain intestinal functions and reduce the risk of gut-
derived infections. The term “use it or lose it” applies 65.  Despite some conflicting 
results, early enteral nutrition has been shown to reduce postoperative sepsis in 
surgical, trauma, and critically ill patients. 66 Therefore critically ill patients need 
very early luminal substrates in order to preserve gut structure and function. As 
we have already seen from the preceding discussion, gut dysfunction and 
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breakdown of the intestinal barrier may play a key role in the development of 
SIRS, sepsis and MOF, even if parenteral nutrition is chosen. The addition of 
early enteral feeding will ensure these added benefits. 
The intestinal mucosa is unable to nourish itself completely from the blood. 
Approximately 50% of the enterocyte and 80% of the colonocyte nourishment 
depends on the luminal supply of nutrients. The lack of luminal substrates in 
starvation leads to atrophy and a rapid down regulation in size and function of the 
intestinal mucosa 67. These morphological and functional changes are reversible 
by enteral, but not parenteral, feeding.This favourable effect of enteral nutrition is 
based on various factors (Figure 1.22). 
 
 
Figure 1.22 Enterotrophic effects of enteral nutrition  
 
The most essential benefits of enteral nutrition are the provision of nutrients and 
energy to the mucosal cells and the stimulation of epithelial cell metabolism by 
direct contact with luminal nutrients, i.e. the renewal of epithelial cells. 65  
 
Other effects of enteral nutrition, which help to maintain gut barrier integrity, are 
the increase in mucosal blood flow and improvement of intestinal perfusion, 
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stimulation of bile flow and pancreatic secretions as well as the release of 
enterotrophic gastrointestinal hormones such as gastrin and enteroglucagon. 65 
 
Most of the clinical studies, comparing total enteral versus total parenteral 
nutrition with respect to infectious outcome, have demonstrated the superiority of 
enteral nutrition. 68 4.When the goal is to support intestinal immunological and 
barrier function, an early start of EN seems to be of utmost importance. 69 4. The 
optimal time to start is, however, an unresolved issue. 70 
 
1.6.1 Optimum time for Initiation of Enteral feeding 
By definition “early enteral nutrition” starts within 24-72 hours after trauma or 
surgery. The immediate post-traumatic contact of the gut with nutrients will likely 
improve the situation in critical illness by several mechanisms. 4 EEN maintains 
or restores immune and gut barrier function.  
 
The clinical consequences are: a better intestinal resorption capacity, improved 
substrate homeostasis and synthesis of visceral proteins, fewer complications 
and reduced gastrointestinal bleeding (Table 1.7).  
 
Randomised trials demonstrated that enteral nutrition is associated with less 
mucosal permeability, enhanced wound healing, improved nutritional outcomes 
and lower costs. Small, unblinded studies showed a decrease in septic morbidity 
in enterally-fed abdominal trauma patients and patients with pancreatitis. 10 
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Table 1.7 Suggested benefits of early enteral nutrition in critically ill 
patients  
 
 
Clinical studies in critically ill patients support the hypothesis that very early 
enteral nutrition, that starts within 4-12 hrs after trauma, significantly improves the 
clinical outcome of patients: Chiarelli et al, were the first who confirmed the 
experimental results in burn patients (n=20). EEN was initiated 4-5 hours after 
admission in the intervention group and in the control group after 55-60 hours. 
The very early fed patients had a lower incidence of positive blood cultures (5 in 
3 patients versus 33 in 7 control patients). It was not stated if the positive blood 
cultures were correlated with intestinal permeability. 4 14 71 
 
It is therefore recommended that enteral nutrition should start within the first 
hours during stress metabolism after trauma, and as soon as the 
macrohaemodynamic situation is stabilised, before breakdown of gut barrier and 
immune dysfunction occurs in critically ill patients. Using an evidence-based 
approach, the recommendation for EEN in critically ill patients is a Level I 
recommendation. 69 72 73  
 
Suchner et al4 concluded that in practice, initiating early enteral nutrition in 
critically ill patients represents a necessity often not realized.  But there is already 
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some clinical data that suggest that very early EN is possible, well tolerated and 
safe even in the most severely ill. If clinically prioritised, the barriers to EEN can 
often be overcome. Braga et al74 evaluated the safety and tolerance of EEN after 
major digestive surgery for cancer in 650 patients. EEN was started within 12 
hours via a naso-jejunal feeding tube or a jejunostomy. Gastrointestinal side 
effects of the EEN were observed in 30% of the patients. Abdominal cramps and 
bloating were the most frequent symptoms, while diarrhoea and vomiting 
occurred less frequently. Most of these side effects were successfully handled by 
reduction or temporary interruption of feeding, or by drugs. Only 59 (8.9%) of the 
patients had to be switched to PN because of refractory intolerance to EN. EEN-
related mortality was 0.1% (1/650). The authors concluded that “the use of the 
gut early after surgery is safe and well tolerated” and should be the “first choice 
for nutritional support in this type of patient”.74  
 
Despite this, there are often contraindications to enteral feeding in this patient 
group as they may not be  easy to stabilise haemodynamically during this period. 
While moving in and out of the ebb phase of stress metabolism, they may  be 
enterally intolerent with ileus and risk of aspiration, particularly to full volume 
feeds. It remains a challenge to achieve enteral-feeding  benefits in these 
patients. 
 
The ESPEN guidelines on enteral nutrition, published in January 2006, 
concluded that no data showed more improvement in relevant outcome 
parameters where early enteral nutrition was used in critically ill patients. 
However, the expert committee recommended early enteral feading (<24h), for 
haemodynamically stable critically ill patients with a functioning gastrointestinal 
tract . No general amount could be given, and the committee recommended that 
nutritional therapy has to be adjusted to the progression/course of the disease 
and taking the gut tolerance into account. If the goal of 20-25ckal/kg BW/day 
enteral nutrition is not met within the first 3 days, then supplementary parenteral 
nutrition should be given. 75  
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The aim should be to start EEN within 6 hours after trauma or surgery and as 
soon as the macrohaemodynamic situation is stabilized 105 4 
 
1.6.2. Optimum Constituents of Enteral Feeds in Early Enteral Feeding 
It seems that nutritionally complete enteral feed is not possible in severe stress 
metabolism because of malabsorption due to structural and functional 
impairments following mucosal injury. Practicability and efficacy of EEN are 
dependent on the pre-existing extent of the mucosal trauma (ischemic mucosal 
damage and mucosal atrophy) and the current degree of intestinal 
hypoperfusion. Absorption and utilization of nutrients is diminished, but the 
digestive capacity can adapt if luminal substrates are supplied .4 14 37  
 
Enteral nutrition exerts its beneficial effects on gastrointestinal functions even if it 
does not constitute the total nutrient need. In patients being fed parenterally, the 
supplementary provision of even small amounts of luminal nutrients can help to 
maintain gut barrier function. Between 10% and 25% of total requirements 
provided by the enteral route seem to be sufficient to support the mucosal 
integrity and decrease the intestinal permeability. 76 77 
 
From the literature there are recommendations to start “minimal” EEN with 5-
10ml of an elemental feed/hour. The feed should be fibre free with a caloric 
density of 1 kcal/ml. Additionally the requirements of energy, protein and other 
essential nutrients can be met parenterally. 4 37  
 
Because the goal of nutritional support has to focus on the preservation of organ 
function during severe stress metabolism 4 37, it can be hypothesised that a 
special enteral feed for the gut  (which contains the preferred substrates for the 
intestinal mucosa, glutamine and butyrate, as well as high antioxidants to 
compensate oxidative stress) will be of much more benefit to the patient than 
common elemental diets. 
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The field of nutritional support therapy has undergone a transformation since its 
conception. Originally artificial feeding was recommended as a means of 
providing energy, proteins, and essential micronutrients to offset muscle wasting 
and prevent starvation-induced immune depletion. Subsequently various dietary 
components have been used in an attempt to modulate immune function. 
Specific amino acids, long chain fatty acids and nucleic acids have been studied. 
Although the composition of nutrition therapy can influence host defense, the 
published literature is divided on the effectiveness of manipulating nutritional 
support formulas to achieve hard clinical endpoints.3 78 
 
1.6.3 Jejunal vs Gastric Enteral Feeding 
It is now recognised that small bowel function and the ability to absorb nutrients 
remain intact despite critical illness, the presence of gastroparesis, and absent 
bowel sounds. In patients unable to tolerate gastric feeding, jejunal feeding may 
still be feasible, allowing the benefits of EEN even in the presence of 
contraindications to gastric feeding. 37 
 
Close monitoring of the patients is very important, because even minimal EN is 
an invasive therapeutic procedure, with the potential risk of gastric colonisation, 
aspiration, obstruction, feeding tube related complications, reflux and diarrhoea. 
The jejunal route of administration may overcome most of these problems. 4 79 80 
 
1.6.4 Volume of Enteral Feeds in Critically ill Patients 
Tolerance of enteral feeding is probably the most commonly used indicator in the 
clinical setting for monitoring the gut function in critically ill patients. 
 
Clinical signs of enteral intolerance are gastric reflux, aspiration, delayed bowel 
movement, abdominal distension, diarrhoea and vomiting (Table 1.8). These 
signs reflect  multiple gastrointestinal disorders such as mucosal injury following 
ischemia and reperfusion, bacterial overgrowth, motility disorders and reduced 
pancreatic functions. 
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Table 1.8 Reasons for and consequences of limited enteral volume in                                                               
the critcally ill 14 
 
Deranged motility 
 
 
 
 
 
 
*gastric reflux 
 
* aspiration 
 
* nausea, vomiting 
 
* abdominal distentions and cramps 
 
* malabsorption 
 
* etc 
 
Reduced exocrine 
pancreatic functions 
 
 
Intestinal hypoperfusion and 
ischemic mucosal damage 
 
 
 
Most critically ill patients do not reach their goal for prescribed enteral nutrition. 
Only 50-75% of the daily dosages are tolerated using standard enteral feed 
preparations. 81 82  
 
There is an interrelation between enteral volume tolerance and clinical outcome 
in critically ill patients.  The patients with gastrointestinal complications in the 
study of Montejo et al 83 who received lower feeding volumes, stayed about 5 
days longer in the hospital and had a significantly higher mortality (31% vs. 16%) 
than the patients without complications. Thus, a limited enteral volume tolerance 
can be a prognostic indicator of the severity of the illness and the clinical 
outcome. 83 
 
Furthermore, a limited enteral volume tolerance means a limited uptake of key 
nutrients for the gut and immune system which decreases the benefits of EEN. A 
limited enteral volume tolerance can directly influence the outcome of critically ill 
patients. Atkinson et al 84 verified that immune-enhancing diets can only improve 
the outcome of critically ill patients, if they receive and tolerate a certain amount 
of the enteral formula  i.e. a certain amount of immunonutrients, which in this 
study translated into > 2500 ml of Impact (formula) within 72 hours of ICU 
admission.  
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Thus, with the currently available standard enteral feed preparations, the limited 
enteral volume tolerance prevents an efficient supply of key nutrients which are 
needed for the benefits of EEN in critical illness.  
 
This indicates the need for new feeds which provide the necessary quantities of 
key nutrients in a lower volume. The Fresenius product Intestamin® has been 
developed to address this need, amongst others, and is the first commercially 
available feed of this kind available in South Africa. 
 
1.7 IMMUNONUTRITION  
 
Over the past decade there has been increasing interest in using specific 
nutrients to modulate the immune system and improve host defense 
mechanisms.  
 
Clinical trials suggested several benefits of immune-enhancing diets, including a 
reduction in infectious complications, ventilator days, and length of ICU and 
hospital stay. 5 85 86   
 
Improvements in clinical outcome with immunonutrition have generally been 
reported in surgical patients, which cannot easily be extrapolated to other patient 
populations. 4 87 
 
Guidelines for the use of immunonutrition, after analyzing the literature, are 
summarized in the table below. 
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Table 1.9 Guidelines for the use off Immune-enhancing diets 
IED - Immune-enhancing diet 
GI - Gastro-intestinal 
 
 
Patients who should receive early enteral nutrition with immune -enhancing diet (IHD) 
  
Elective GI surgery 
 
 
  
moderate / severely malnourished patients (albumin < 
3.5g/dL) undergoing elective esophageal, gastric,  
pancreatic, or hepatobiliary surgery 
  
 
  
more severely malnourished patients would likely benefit the 
most 
 
  
severely malnourished patients with albumin <2.8g/dL 
undergoing colonic and rectal surgery 
 
Blunt and penetrating 
torso trauma 
 
 
  
Patients with ISS > 18; score correlates with injuries to two or 
more 
 
body systems with a severe injury in at least one site 
 
 
  
Patients with ATI > 20; score correlates with severe injuries to 
the colon, pancreas, liver, duodenum, and/or stomach 
 
Patients who may benefit 
from IED , but data are 
limited. (elective surgery) 
  
  
 
  
Pat ients undergoing aortic reconstruction with known chronic 
obstructive pulmonary disease. 
  
 
  
Patients with pre-existing malnutrition undergoing major head 
and neck surgery. 
 
 
  
Patients with third - degree burns > 30% total body surface 
area burn. 
 
 
  
Patients who are ve ntilator dependent, nonseptic, medical and 
surgical patients at risk of subsequent infectious morbidity. 
 
Patients in whom early 
enteral feeding or IED s 
are inappropriate 
 
 
  
Admitted to the ICU for monitoring only. 
 
 
  
Expected to resume an oral diet within 5 d ays 
 
  
Have a bowel obstruction distal to the site of access for 
enteral feeding. 
 
 
  
Have major upper GI hemorrhage caused by varices or peptic 
ulcer disease. 
 
 
  
Are incompletely resuscitated with poor splanchnic perfusion. 
 
  
   
50 
1.7.1 Dietary Components with Immune-modulating effects 
 
1.7.1.1 Glutamine 
Glutamine is the most prevalent free amino acid in the human body. In skeletal 
muscle, glutamine constitutes > 60% of the total free amino acid pool. Glutamine 
was classified as a non-essential amino acid when it was demonstrated that it 
could be synthesized in the body, predominantly in the skeletal muscle. However 
glutamine should be reclassified as a conditionally essential amino acid in the 
catabolic state, because the body´s glutamine expenditure exceeds synthesis 
and low glutamine levels in plasma are associated with poor clinical outcome.14 88  
 
In normal metabolism, glutamine synthesis and expenditure are well balanced. 
Consequently, a state of deficiency does not exist and the amino acid may fulfill 
its important functions. The main functions of glutamine are illustrated in Figure 
1.23 and include two main areas, namely metabolic fuel for rapidly proliferating 
tissues such as the enterocytes, endothelial cells, immune cells and the renal 
tubular cells, and a precursor for biosynthesis of peptides (protein), glutathione 
and nucleotides.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23 Metabolic functions of glutamine  
(Source: Martindale RG, Sawai R. 200714) 
 
Metabolic fuel for rapidly 
proliferating tissues (provides 
ATP ) 
Enterocytes 
Endothelial cells 
Immune cells 
Renal tubulus cells 
Precursor for biosynthesis 
Peptides / protein 
Glutathione 
Nucleosides / nucleotides 
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However, one of the immediate responses to trauma or surgical stress and, in 
particular to corticosteroids, is the increased export of glutamine from the free 
amino acid pool in muscle to the intestinum and immune system. 14  
 
Glutamine is therefore required in increased amounts to manifest optimal tissue 
responses to catabolism, inflammation and infections,  and endogenous 
synthesis cannot keep pace with increased demands in these conditions.  In the 
catabolic state, the provision of conditionally essential glutamine should be 
considered a necessary replacement of deficiency rather than a 
supplementation89. 
 
The frequently high requirements of glutamine in critically ill patients cannot be 
met with the available enteral immunonutrition formulas, even when the patients 
tolerate the full recommended dosage of 1.5-2 l/day. 
 
It is recommended that a postoperative patient receive about 1,5 g protein/kg 
body weight per day. The usual glutamine dose in this individual should be about 
0,3 g/kg body weight per day. For a 60-70kg patient this provides about 20g 
glutamine/d. A severely injured patient with multiple trauma represents a more 
severe state of stress. Such a patient would therefore require more glutamine, up 
to 30 g/d. 90 
 
To achieve such a high glutamine supply with currently available ready-to-use 
tube feeds, would imply an intake up to 2,5-3 litres per day, as immunonutrition 
diets roughly contain 1g glutamine/100ml as part of a whole protein source. Such 
a high volume will definitely not be tolerated by critically ill patients within the first 
days of enteral feeding. 
 
An innovative approach using glutamine containing dipeptides in enteral nutrition 
facilitates high dosage glutamine therapy with ready-to-use tube feedings within a 
low volume for the first time 
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It seems logical that considerations should be given to giving glutamine very 
early on in the course of a critical illness, to remedy firstly any immune system 
dysfunction and secondly to prevent any further deactivation of the immune 
system. This approach has already shown promising results in randomised 
clinical studies. In one randomised controlled study, glutamine supplemental 
enteral nutrition (up to 30 g/d) was commenced within 48 hours of trauma via a 
nasoduodenal tube for a minimum of 5 days. There was a significant reduction in 
the 15 day incidence of pneumonia, bacteraemia and severe sepsis. 
Measurement of the soluble TNF (Tumour Necrosis Factor) receptors, as a 
marker of a systemic inflammatory response, demonstrated that patients with 
glutamine supplementation had a lower systemic inflammatory response than 
control patients. In another study, early enteral glutamine supplemental feeding 
was commenced in  multi-trauma critically ill patients within 48 hours. Rapid 
increase in feed volume via a naso-jejunal tube, such that by the 3rd-4th day they 
received between 25-30g glutamine/day. There was no overall survival difference 
but significant reduction in infectious morbidity in the first 15 days. 89 
 
In both groups mean plasma glutamine concentrations were below the lower limit 
of a reference range on day one. Compared with the control group, significantly 
higher concentrations of glutamine were seen on day 3, 4 and 5 in the glutamine 
group. Hence these studies showed that glutamine-enriched enteral nutrition can 
increase plasma glutamine concentrations in critically injured patients and 
improve patients´ outcome. Jones et al conducted a randomised double-blind 
study in a more heterogeneous group of adult patients in the intensive care unit . 
Some patients were already infected, but able to tolerate enteral feeding.  
 
The supply of 18g/d glutamine to these patients resulted in significantly reduced 
post-intervention hospital cost. They conclude that in critically ill patients in the  
intensive care unit, enteral feeds containing glutamine result in significant 
hospital cost benefits 91 92. 
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Three sites of action may be considered, representing potential targets for 
glutamine:  
 
 Mucosal barrier function 
 Cellular defense function 
 Local or systemic inflammatory response 
 
Mucosal barrier 
Glutamine is a major source of energy for the rapidly dividing cells of the 
gastrointestinal tract (enterocytes, colonocytes) and the GALT represents an 
essential substance for maintenance of gut metabolism, structure and  
function.  9 14        
 
Sufficient availability of suitable substrates e.g. glutamine as well as early enteral 
nutrition are currently considered the major tools in maintaining the structure and 
functionality of the mucosal barrier. 4 14  
 
Cellular defense 
The nitrogen component of glutamine appears to play an important role in the 
maintenance of gut structure and function. It is a major component for the 
biosynthesis of nucleotides (playing a major role in proliferation) and amino 
sugars (playing a major role in lining of the gastrointestinal tract).  
 
Inflammatory response 
In addition, glutamine-mediated glutathione synthesis is probably one of the most 
important factors when considering treatment for the systemic inflammatory 
response. It is proposed that glutathione synthesis is a crucial factor in the 
reversal of the clinical and biochemical signs of critical illness. 4 14  
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1.7.1.2 Arginine  
Suchner et al hypothesised that specific immune-enhancing nutrients, especially 
arginine, may unfavourably intensify systemic inflammation and consequently 
worsen the outcome in critically ill patients, because of its proinflammatory 
effects. 93 
 
The supplementation of arginine (like the other key nutrients for immunonutrition) 
is based on the observation that these nutrients become depleted in critical 
illness due to extensive consumption. But it might be possible that the availability 
of arginine in critical conditions needs to be lower than normal in order to avoid 
harmful effects in certain circumstances. Thus, not all substrates need to be 
replenished, because adequate levels have to be defined in accordance with the 
underlying pathophysiology. 93 
 
Moreover, arginine has been insufficiently investigated compared to other 
immunonutrients such as glutamine.  
 
1.7.1.3 Short chain fatty acids (SCFA) 
The SCFA butyrate is a key substrate for intestinal nutrition, maintenance of 
mucosal integrity and restoration. Mechanisms by which SCFA may mediate 
intestinal proliferation and function include stimulation of local blood flow, 
production of exocrine pancreatic secretions, stimulation of the autonomic 
nervous system, and production of enterotrophic hormones. 7 14 37  
 
Usually butyrate is produced from dietary fibre in the large intestine (colon). 
However the supply of dietary fibre can be linked with some unwanted effects 
(such as abdominal distension, bacterial overgrowth and the risk of intestinal 
obstructions) in critically ill patients. Dietary fibre is thus contra-indicated in 
critically ill patients.  
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An alternative to the enteral fibre supply can be the supplementation with SCFA. 
Several experimental and clinical studies have shown beneficial effects of orally/ 
enterally and parenterally administered SCFA. For example, SCFA stimulated 
intestinal mucosa proliferation, reduced small bowel atrophy during TPN and 
enhanced intestinal adaptation after bowel surgery . 94 
 
It could therefore be stated that SCFA are essential to support the gut barrier in 
critical illness because of their importance as main fuels for the intestinal 
mucosa. 95  
 
Intravenous infusion of SCFA (sodium butyrate, acetate and propionate) 
significantly reduced small bowel atrophy, which was caused by starvation of the 
gut, during parenteral feeding of rats.  
 
Because of the above-mentioned benefits of butyrate, this nutrient is important in 
the support of the gut in critically ill patients. It is postulated from in vitro results 
that for the stimulation of intestinal cell proliferation and the maintenance of 
mucosal integrity, a dosage of 10-20 mmol butyrate will be effective. This dose 
reflects the minimum of the normal daily butyrate production from undigested 
carbohydrates in the large intestine which is about 10-60 mmol.  
 
1.7.2 Intestamin 
Intestamin®  is a small volume enteral immunonutritional supplement which 
provides supplementation of parenteral feeds with small volumes of 500ml per 
day (24 hours), which is a lower volume and therefore better tolerated than 
standard enteral feeds for similar essential enteral supplementation.  
 
Semi-elemental substrates in the form of glutamine dipeptides, glycine and 
tributyrine provide energy substrates even in the absence of functional digestive 
processes. Intestamin® offers a new source of one of the most important 
intestinal fuels, the SCFA butyrate – in form of the structured lipid “Tributyrin”. 
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Tributyrin (1,2,3-Tributyrylglycerol= C15H26O6) is a structured lipid consisting of 
three molecules of butyrate esterified with glycerol.  Both components of 
tributyrin, butyrate and glycerol, are normal intermediate products in human 
metabolism. Besides the supply in milk fat, butyrate is produced by microbial 
fermentation of dietary fibre in the large intestine. Glycerol is an intermediate 
substance in fat metabolism which is produced during normal digestion. 
Industrially produced tributyrin is used as a “naturally identical flavouring food 
additive” in baked goods, beverages, fats and oils, dairy desserts and other 
foods.  
 
For these purposes tributyrin is “generally recognised as safe” (GRAS) by the US 
Food and Drug Administration (FDA: 21CFR184.1903).  
 
Selective antioxidant additives include glutamine, antioxidant vitamins, selenium 
and zinc. Research has postulated that the dose and combination of additives 
chosen for Intestamin® have an advantage over other standard feeds, as a 
greater concentration is available in a smaller volume for enhanced absorption 
and tolerance.  
 
Arginine has been omitted based on the studies which have suggested that it 
may worsen the outcome. 14 20  21 37 101 
 
Intestamin® (manufactured by Fresenius Kabi, Bad Homburg, Germany) content 
per 500ml contains: 
 • 259k cal  
 • 1g tributyrin (as a substitute for fiber) 
 • 30g glutamine 
 • 300g selenium 
 • 20mg zinc 
 • 1500mg vitamin C 
 • 500mg vitamin E  
 • 10mg carotene 
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The manufacturer’s recommendation for  the use of  Intestamin® is as an enteral 
supplement in combination with parenteral and/or enteral nutrition, as it contains 
antioxidant vitamins, and trace elements, glutamine, and SCFAs. 
 
1.8 MOTIVATION FOR THE STUDY 
Studies evaluating immune-modulating diets (IMD) have suggested that they are 
associated with a number of beneficial effects, including a reduction in infectious 
complications, fewer days on antibiotics and ventilator, and shorter ICU and 
hospital stay. These effects, in turn, have been shown to be associated with cost 
benefits. There has been concern, however, that better outcome is observed only 
in patients who tolerate significant amounts of enteral nutrition. Thus, the claimed 
benefit cannot be extrapolated to all patients. In fact, critically ill patients with 
severe sepsis, shock and organ failure not only do not benefit, but may actually 
be harmed by treatment with IMD, since current immunonutrient supplemental 
products are unsuitable for this type of patient.96 79 Major problems arising from 
current IMD are: inadequate provision of ‘key nutrients’ via the enteral route due 
to feeding intolerance, lack of short chain fatty acids due to reduced enteral 
tolerance of fiber, insufficient capacity to counteract free radical induced damage 
of the intestinal barrier, administration of pro-inflammatory and free radical 
generating substrates. 
 
Research has been directed at finding the optimum nutritional composition, 
timing and route to support the very important immune and barrier functions of 
the gastrointestinal tract in critically ill patients. It can be hypothesised that certain 
substrates added to standard enteral feeds can modulate the immune response 
and may decrease infectious morbidity in these patients, and that the introduction 
of early enteral feeding has significant benefits on maintenance of gut integrity. 
 
Bearing this in mind, what would constitute the ideal early enteral feed in these 
patients and how does this translate into a choice between enteral feeds?  
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As digestive processes can be assumed to be partially or entirely dysfunctional in 
critical illness,  a supplemental enteral feed, aiming to provide caloric support, 
must do so in a form which is easily absorbable despite gut dysfunction. Semi-
elemental feeds would be expected to be better tolerated and more easily 
absorbed. 
 
Currently available immunonutrition formulas provide effective dosages of key 
nutrients in daily volumes of 1500-2000 ml. The common dosage scheme 
recommends 20-25 ml/h to start with, which amounts to a total of about 500 ml 
on the first postoperative/post-traumatic day. The feeding volume is then 
increased stepwise to approximately 750 ml on the 2nd day, 1000 ml on the 3rd 
day and further, to the complete daily dosage of 1500 ml on the 4th or 5th day.97 
 
However, there are many critically ill patients who do not tolerate a daily dosage 
of 1500 ml of an enteral feed on the 4th or 5th postoperative day. Especially the 
most severely ill patients, frequently suffer from intolerance to enteral feeding. 
Some of these patients tolerate only very small amounts of an enteral feed, 
others do not tolerate enteral feeding at all. 
 
Ideally the enteral feed chosen for these patients should include the caloric 
requirements in the smallest possible volume for maximum tolerance. 
 
From the previous discussions, we can conclude that certain supplements will be 
advantageous for a positive effect on the stress cycle.  Antioxidants and 
immunoactive substrates like glutamine have been shown to have the potential 
for additional benefit, and therefore  selective enrichment with these substances 
may result in further potential benefits. 
 
With the above points in mind, Intestamin® has been formulated as a unique new 
enteral supplement which may be considered one of the second generation 
enteral supplemental feeds and could be associated with improved outcomes in 
crtically ill patients. 
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This study was undertaken to test this hypothesis by using selected infection 
markers, duration of ventilation and ICU stay as surrogate markers for outcome 
in a population of critically ill patients. 
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CHAPTER 2 : METHODOLOGY 
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2.1 STUDY AIM 
 
The aim of the study was to investigate the effect of Intestamin® administration 
to critically ill patients on the prevalence of infection, ventilation requirements and 
duration of Intensive Care Unit (ICU) stay.  
 
2.2 OBJECTIVES 
 
The primary objectives were to: 
• determine if Intestamin® administration decreases infection rate in the 
critically ill patient, 
• determine if Intestamin® administration decreases ventilation days in the 
critically ill patient, 
• determine if Intestamin® administration decreases the length of stay in the 
ICU for the critically ill patient. 
A secondary objective was to assess the tolerability of early enteral nutrition 
supplementation with Intestamin® in critically ill patients. 
 
2.3 HYPOTHESIS 
 
Intestamin® administered to the critically ill patient has beneficial effects on the 
prevalence of nosocomial infection rates, ventilation requirements and duration of  
stay in the ICU. 
 
2.4 STUDY DESIGN AND STUDY POPULATION 
 
The study design was an open label, retrospective, case control, analytical study, 
of patients admitted to the adult general ICU of Netcare The Bay Hospital, 
Richards Bay, Kwazulu Natal, between June 2003 and November 2003, who 
were treated with Intestamin® supplementation, in addition to the normal nutrition 
support, according to standard practice protocols. Data from the patients who 
met the inclusion criteria for the study was collected on a daily basis by the 
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researcher. Matched case controls were evaluated from the files of patients who 
were admitted to the same ICU between January 2002 until end off May 2003, 
but who were not treated with Intestamin®.  
 
The data from the matched case controls was collected from the clinical records 
and laboratory records of demographically matched patients with similar 
conditions to the intervention group. The control group were matched with the 
intervention group, making use of the APACHE 2 scoring system.60 These two 
groups were considered comparable as there were no protocol changes in the 
ICU management in this unit during the stated periods and the management was 
directed by the same senior clinicians. The diagnostic criteria and treatment 
procedures would therefore be expected to stay the same, except for the use off 
Intestamin® in the intervention group. 
  
The Bay Hospital ICU is a nine bed unit fully equipped to deal with medical, 
surgical and trauma patients in need of intensive care treatment. Each patient 
has a dedicated registered nurse, who is responsible for all the nursing needs of 
the patient, continuous monitoring and observations and collection of laboratory 
samples. Physiotherapy by registered physiotherapists occurs twice daily for 
chest physiotherapy and the collection of sputum aspirate samples, as requested 
by the overseeing physician.  
 
2.5 PATIENT SELECTION 
 
Patients were selected for the study from post-surgery and post-trauma patients 
at high risk of SIRS and severe sepsis and critically ill patients with established 
SIRS or severe sepsis. This included patients following major surgery, severe 
burns, severe head injury, severe blunt or penetrating torso trauma and acute 
pancreatitis. 
 
Patients were excluded from the study if enteral feeding was medically 
contraindicated. This included patients with obstructive ileus, major upper GI 
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haemorrhage, caused by varices or peptic ulcer disease with a visible vessel on 
endoscopy, patients with impaired swallowing reflex, severe acute necrotising 
pancreatitis, metabolic coma (e.g diabetic, hepatic coma), uncompensated 
circulatory shock (ebb phase of stress metabolism), intractable diarrhoea (> 1500 
ml watery stools/day), intestinal fistula (> 500ml output/day), small bowel 
necrosis following intestinal hypoperfusion and acute colonic pseudo-obstruction.  
 
2.5.1 Inclusion criteria: 
 ICU admission 
 Male and female patients 
 Age 18-75 years 
 High probability of developing SIRS or signs of SIRS as indicated by an 
APACHE II score of > 18 
 Expected mortality of < 70%  as indicated by APACHE II score of < 31 
 Patients on mechanical ventilation 
 
2.5.2 Exclusion criteria: 
 Age < 18 or > 75 
 APACHE II score < 18 
 APACHE II score > 31 
 Patients not mechanically ventilated 
 Patients in whom enteral feeding was medically contraindicated 
 
The APACHE II score (Addendum A) is a general measure of disease severity 
based on physiological measurements, age and previous health condition.  It is 
used in clinical research to stratify patients according to the severity of the 
disease in critical illness. This score was used to match patients in the control 
and intervention groups according to disease severity.60  
 
The sample size of 12 patients in the intervention group was determined by the 
preset time lines of the study - of 6 months - for recruitment. During this period 
only 12 suitable patients met the inclusion criteria for the active arm of the study 
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from a total of 60 screened and these were then matched demographically and 
for disease severity with 12 retrospective controls. As a result of the small sample 
size, and bearing in mind that trials of enteral nutrition in this patient population 
usually need large numbers for statistical significance, it was recognised at this 
point that the trial would have to be considered as a pilot study on the subject, 
and would be unlikely to be definitive in its findings. 
 
2.6 PATIENT  NUTRITION SUPPORT 
 
2.6.1 Nutrition Support Regime 
Patients included in the intervention group received Intestamin® supplementation 
within 24 hours after enrollment in the trial, at 10ml/hr, increasing the rate by 
10ml/hr every four hours to reach a target of 500ml/day within 48 hours. After 
four hours of supplemental feeding, the feed was stopped for one hour, 
nasogastric aspirate was done by the registered nurse looking after the patient 
and a supplement feeding protocol was followed. The protocol required that when 
nasogastric aspirate was less than 50% of the total amount of supplemental feed 
fed, the supplemental feed (Intestamin®) would be increased by 50% of the 
current running rate. The Intestamin® was given to the intervention group for a 
five day period. Complete enteral formulas (disease-specific) were introduced 
from day 2, together with Intestamin®, at a running rate of 35ml/hr and the same 
feeding protocol was followed to increase the running rate of the complete enteral 
formulas.  Following the ICU’s feeding regime, nutritional needs for each patient 
were calculated individually to supply 25kcal/kg. All enteral feeds were given via 
the nasojejenal route. When any feeding intolerance was encountrered, the 
Intestamin®  was not decreased or stopped, but the complete enteral feed was 
either changed to another feed or TPN was initiated. 
  
Gastrointestinal tolerance was assessed daily in all patients by clinical 
examination. Signs considered indicative of gastrointestinal intolerance included: 
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1. Abdominal distention or bloating. If the abdomen was distended, but soft 
to palpation, a 48 hour waiting period was initiated with no change in the 
feeding but close monitoring. If abdominal distention persisted, and the 
patient was already on a standard enteral feed, it was changed to a semi-
elemental feed together with Intestamin®. If symptoms persisted for 
another 48 hours, standard enteral feeding was stopped and TPN was 
commenced, but Intestamin®. was still continued. Only if the intolerance 
continued or worsened in the 24 hours after changing to TPN, would the 
Intestamin then be stopped or temporarily interrupted. 
 
2.  Intractable diarrhoea. This was defined as more than 1500ml watery 
stools/day. If this was observed, standard enteral feeding was stopped  
and TPN was commenced. The Intestamin® was continued, and only if 
the diarrhoea persisted despite the change to TPN, would the Intestamin® 
be discontinued. 
 
3.  Gastroparesis. When nasogastric drainage was more than 500ml/24 hours 
only Intestamin® in combination with TPN was used until nasogastric 
drainage was less than 150ml/24hours, at which point standard enteral 
feeding was reintroduced.  
 
4.  Nausea and Vomiting. If the patient demonstrated nausea and vomiting, 
the running rate of the standard formula was decreased by half. The  
Intestamin® running rate was continued unchanged. If the symptoms were 
relieved within 24 hours, the standard formula was reintroduced at the 
previous running rate. If symptoms persisted, standard enteral feeding 
was stopped  and TPN was commenced. The Intestamin® was continued, 
and only if the nausea and vomiting persisted despite the change to TPN, 
would the Intestamin® be discontinued. 
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2.7  DATA COLLECTION 
 
Development of respiratory and urinary sepsis were used as surrogate markers 
for progression to severe sepsis and SIRS. Additionally, duration of ventilation 
and ICU stay were considered representative of the response to treatment and 
degree of clinical complications. The following information was collected for each 
patient studied: 
1. At entry to the study and weekly: urine chemistry, microscopy and culture, 
sputum microscopy and culture, blood culture. 
2. At entry to the study and daily according to standard ICU protocol: vital 
signs including temperature, heart rate, blood pressure, urine output, fluid 
intake, full blood count including serum haemoglobin and white cell count, 
urea and electrolytes, blood glucose. 
3. At entry to study and weekly: Liver function tests including serum albumin, 
serum calcium, magnesium and phosphate, chest X-ray. 
4. As indicated clinically (based on clinical suspicion of infection): urine 
catheter tip culture, sputum microscopy and culture, blood culture, central 
line tip culture, chest X-ray. 
 
Where sputum could not be produced spontaneously or with physiotherapy 
assistance or in patients with tracheostomies, tracheal aspirate specimens were 
taken for microscopy and culture instead of sputum specimens. 
 
All sputum specimens for culture were taken by the ICU trained nursing staff or 
physiotherapist using standard aseptic technique and protocols for this ICU. 
 
All urine specimens for culture were taken after the catheter was clamped for 10 
minutes  by the ICU trained nursing staff using standard aseptic technique  and 
protocols for this ICU.  
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All laboratory haematology blood microbiology and chemistry specimens were 
taken by the ICU trained nursing staff or laboratory phlebotomist using standard 
aseptic technique  and protocols for this ICU and hospital. 
 
Chest X Rays were perfomed by one of the radiographers of the private radiology 
practice of Drs Nisbet and Govender and reported by one of the specialist 
radiologists in the practice. 
 
Clinical evaluations were performed by the specialist surgeon in charge of the 
case, Dr P van Rooyan or Dr G Kelling. 
 
In addition, duration of ICU stay and duration of mechanical ventilation were 
calculated from the clinical records and ICU charts by the principal investigator 
with 1 day being from 06.00 to 05.59 the following day. 
 
Blood, urine and sputum specimens were analyzed by an accredited private 
laboratory, Drs Bouwer & Partners, Richards Bay Laboratory, (Ampath National 
Laboratories facility, accreditation number: M0153; ISO accredited; ISO 
15189:2003, expires May 2011) using standardized verified techniques 
performed by registered pathology technologists.  
 
The blood samples were analysed using the ADVIA 120 Haematology system. 
For white blood count, the whole blood sample is mixed with ADVIA 120 BASO 
reagent that contains acid and surfactant. The red cells are haemolyzed, and the 
white blood cells are then analyzed using 2 angle scatter signals. 
 
The Beckman SYNCHRON CX system was used to analyse the liver function 
tests by making use of an enzymatic rate method for each individual liver enzyme 
test. 98 
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With the Beckman SYNCHRON CX system, Albumin Reagent is used to 
measure albumin concentration with a timed-endpoint method. In the reaction, 
albumin combines with bromcresol purple to form a colored product.98 
 
Total Protein Reagent is used to measure the total protein concentration by a 
timed-endpoint biuret method. (Beckman SYNCHRON CX system). 98 
 
The Beckman SYNCHRON CX4 system was used to determine the 
measurements of sodium, potassium, chloride, carbon dioxide, glucose, urea 
nitrogen, creatinine and calcium in various serum specimens. Each test is 
performed using specific electrodes and individual chemistry reactions. The 
concentration signals originating at the electrodes in the flow cell, and the 
sensors in the reaction cups are converted by analog amplifiers to actual 
concentration values. 98 
 
Endotracheal and sputum specimens were cultured by innoculation using a 
sterile swab on Colombia blood agar plate (5% CO2) with Optochin disc in pool, 
Chocolate agar plate (5% CO2) or MacConkey plate (O2). Gram stain was 
applied. The laboratory reported on the Gram stain, microscopic morphology and 
the quantification of all bacteria seen in relationship to the cell types that were 
present. 
 
Urine specimens were macroscopically examined before being processed for 
abnormal color and the presence of blood. Thereafter quantitative cultures were 
performed on the specimens, making use of Sheep blood agar plates, 
MacConkey agar plates, Mueller Hinton agar plates and to detect antimicrobial 
substances present, Antimicrobial Substance Plates, were used.  
 
All patient data was collected by the principal investigator from the patient charts 
and transcribed to an Excel data sheet. This dataset was sent for statistical 
analysis to the statistician.   
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Quality control at Ampath Laboratory is done internally as well as externally. For 
liver function tests, Synchron Level 1,2 and 3 are run daily, for full blood count 
ACT5 Normal, Low and High are run daily. A  day-to-day variation of < 7% being 
the highest variance for a given determination. The laboratory belongs to the 
THISTLE EQA program, which covers Haematology and Clinical Chemistry 
external quality control, and these samples are run monthly.  
 
2.8  DATA ANALYSIS 
 
All the results were collected and entered in a dataset making use of Microsoft 
Excel® in consultation with the appointed statitician. All statistical analyses were 
performed with the help of a statistician, Prof DG Nel, appointed by the Faculty of 
Health Science, Stellenbosch University. 
 
Summary statistics were used to describe the variables.  Variables were 
presented graphically in the form of histograms or frequency tables to see the 
nature of the distribution of the particular variables and to be able to identify 
possible outliers. Medians or means were used as the measures of central 
location for ordinal and continuous responses, and  standard deviations and 
quartiles as indicators of spread. The Means (x) and standard deviations (SD) 
were reported where necessary for continuous or ordinal response variables in 
the format: x [SD].  Tables with many characteristics of the variables involved, 
namely the mean value, the median (50th percentile), the mode (value with the 
highest frequency), the quartiles, the maximum and minimum values, standard 
deviation, were  included in the descriptive statistical methods where relevant.  
 
Chi-Square and Fisher’s exact test were used for comparison of nominal or 
frequency data between groups. All reported p-values less than 0.05 were 
considered as significant for all tests performed.  
 
Repeated-measures analysis of variance was used to evaluate treatment-related 
effects over time. Descriptive statistics were given for the different groups 
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compared. The Mann-Whitney test was used, and where more than two groups 
were compared the Kruskal-Wallis test was used. Normal probability plots of the 
residuals were done to determine whether data was normally distributed. 
 
2.9 ETHICAL CONSIDERATIONS 
 
The study was approved  by the Committee for Human Research of the Faculty 
of Health Sciences, Stellenbosch University (N04/10/166) (Addendum C) and 
conducted according to ICH GCP guidelines (Guidance on Good Clinical Practice 
and regulations by International Conference on Harmonization). Permission to 
access retrospective clinical data for this pilot study was granted by the treating 
surgeon in charge of each case and by the Bay Hospital Manager, Mrs B Moore. 
(Addendum D) 
 
Each enrolled patient’s identification information was omitted from study-related 
material to ensure participant anonymity and confidentiality. Upon entering the 
study, each participant received a unique subject identification identity number, 
which was used on all study-related material and documentation.  
 
The data collected was only used for this specific study, and was not shared for 
any other purposes or studies. 
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CHAPTER 3: RESULTS 
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3.1 DESCRIPTION OF SAMPLE 
 
A total of 60 patients, admitted to The Bay Hospital ICU between June 2003 and 
November 2003, were screened retrospectively, of which 12 met the entry criteria 
and were included in the study. Twelve controls who also met the criteria were 
selected from hospital records after a review of archived patient files.  
 
The patients were matched in the intervention group (N = 12) and the  control 
group (N= 12), using the APACHE II score (Addendum A)  and demographics of 
each patient . 
 
All patients included in the intervention group received Intestamin® enteral 
supplementation during the course of the study period.  
 
The two groups were demographically comparable with no statistically significant 
differences between age and sex distribution (Table 3.1). Ages ranged in the 
intervention group between 22-77 years of age with a mean of 45.75 [16.24] 
years and in the control group between 28-67  with a mean of 46.42 [12.72] years 
of age. 
 
Elective post surgery and emergency post surgery patients were included in both 
groups with mean APACHE II scores of 24 (range 20-29) in the intervention 
group and 24 (range 18-30) in the control group (Table 3.1). 
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Table 3.1  The sociodemographic characteristics of the patients included 
in the study 
Variable Control Group (CG) Intervention Group (SG) 
 Male Female Male Female 
Number (N) 9 3 8 4 
Number per 
Group 
12 12 
Age mean 
[SD] 45.67 [14.41] 48.67 [7.02] 45.13 [19.09] 47.00 [10.68] 
Group Age 
Mean [SD] 46.42 [12.72] 45.75 [16.24] 
P - value 0.60 
APACHE 
score / Group 
25.00 [5.89] 22.33 [9.45] 23.75 [19.09] 25.25 [6.4] 
P - value 0.78 
Elective 
Postoperative 
Patient 
6 3 5 3 
Emergency 
Postoperative 
Patient 
3 0 3 1 
Mann-Whitney U test significant if p < 0.05. 
[SD] = Standard Deviation 
APACHE = Acute Physiological Assessment and Chronic Health Evaluation 
 
3.2  PATIENT NUTRITION SUPPORT 
 
Patients included in the intervention group received Intestamin® supplementation 
within 24 hours after enrollment in the trial at 10ml/hr, increasing the rate by 
10ml/hr every four hours to reach a target of 500ml/day within 48 hours. On day 
one, the intervention group received between 105ml-483ml of the supplement 
(Intestamin®). From day two the intervention group received the planned 
500ml/day. The supplement Intestamin® was given to the intervention group for 
a five day period. Complete enteral formulas (disease-specific) were introduced 
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from day 2, at a running rate of 35ml/hr, increasing the rate by the same protocol 
that was followed when increasing the running rate of the complete enteral 
formulas. Complete enteral formulas reached a mean volume of 840ml on day 2, 
increasing to between 960ml-1320ml/day for the remainder of the period while 
enteral nutrition was needed. All enteral feeds were given via the nasojejenal 
route, and continued for at least 10 days. When any feeding intolerance was  
encountered, the Intestamin was not decreased or stopped, but the complete 
enteral feed was either changed to another feed or TPN was initiated. 
 
Only minor gastrointestinal intolerance was experienced in the form of diarrhoea , 
occuring in only one of the patients in the intervention group, however this was 
less than 1500ml per 24 hours and lasted for only one day and no patient had to 
discontinue Intestamin® enteral feeding during the study. 
 
3.3  INFECTION INDICATORS 
 
3.3.1  Respiratory Infections 
Five variables were collected in respect to respiratory infections: temperature 
spike and elevated white cell count, chest X-ray changes suggestive of infection, 
pus cells in the sputum or tracheal aspirate and positive culture in the sputum or 
tracheal aspirate.  
 
For the purposes of this thesis: 
 
Suspected Respiratory Infection: was defined when two or more of the 
variables (Table 3.2) were positive. The temperature spike and elevated white 
cell count were only considered significant if they occurred with other signs or 
symptoms of respiratory disease as opposed to an alternative site of sepsis.  
 
Confirmed respiratory infection was defined when a positive culture was 
supported by one other variable.  
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Tabel 3.2 Variables supportive of respiratory infection  
Variable Description 
Temperature spike Temperature measure above 36.8ºC 
Positive culture growth in tracheal 
aspirate 
Laboratory confirmed positive bacterial 
culture from tracheal aspirate sample  
Chest X-ray findings suggestive of 
infection 
Pulmonary infiltration opacification or 
consolidation as reported by a 
Radiologist 
Presence of pus cells in tracheal 
aspirate 
Pus cells seen on microscopy by the 
laboratory tracheal aspirate specimen 
Raised white blood count White blood count of greater than 10 x 
10ˆ9/L,  on peripheral blood sample as 
measured by the laboratory. 
 
Categorical data analysis of the respiratory indicators of infection used for the 
purpose of this study, between the intervention and control group, was done 
using the Mann-Whitney U test.  
 
This showed no statistically significant difference between intervention and 
control group for temperature spikes (p=0.54), white blood count (p=0.95) or 
chest x-ray findings (p=0.47) (Table 3.3).  
 
However, statistically significant differences were found  between the two groups 
for  the presence of pus cells (p=0.003) and positive culture growth in the 
tracheal aspirate specimen (p=0.033) (Table 3.3).  
 
The intervention group showed a higher incidence of pus cells and the control 
group a higher incidence of culture growth. 
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Table 3.3:  Respiratory indicators of infection used in the study 
Group Temperature 
spikes 
Mean  
[Standard 
Deviation] 
Tracheal 
aspirate 
culture 
growth 
Mean 
[Standard 
Deviation] 
Pus cells in 
traceal 
aspirate 
Mean 
[Standard 
Deviation] 
 
Chest X-ray 
confirming a 
chest 
infection 
[Standard 
Deviation] 
White 
Blood 
count total 
Mean 
[Standard 
Deviation] 
 
Control  
Group 
 
Intervention 
Group 
 
3.92 [1.62] 
 
 
5.33 [1.62] 
 
2.67 [4.85] 
 
 
0.00 [0.00] 
 
0.00 [0.00] 
 
 
2.50 [4.50] 
 
12,46 [5.73] 
 
 
14.32 [6,72] 
 
13.97 [5.61] 
 
 
14.32[1.65] 
 
 
p - level 
 
 
p = 0.54 
 
 
 
p = 0.033 
 
 
 
p = 0.003 
 
 
 
p = 0.47 
 
 
p =0.95 
(Mann-Whitney U Test significant if p < 0.05) 
 
 
A statistically significant difference was found between suspected and confirmed 
infections within the intervention group in favour of fewer confirmed respiratory 
infections (p=0.01), but no statistically significant difference between suspected 
and confirmed infections in the control group (p=0.14) (Table 3.4). 
 
 
Overall, between the intervention and control groups, there was statistically fewer 
confirmed respiratory infections in the intervention group (p=0.05) but no 
statistically significant difference between the two groups for suspected 
respiratory infections (p=0.2). (Table 3.4) 
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Table 3.4   Confirmed and suspected respiratory infection 
 
Suspected 
Respiratory 
infections Mean 
[SD] 
Confirmed 
Respiratory 
infections Mean 
[SD] 
p-value within a 
group 
Intervention 
Group 
6.67 [8.08] 0.08 [0.28] 0.01 
Control Group 3.33 [3.33] 1.58 [2.47] 0.14 
P-value between 
groups 
0.2 0.05  
ANOVA – test significant if p < 0.05 
 
 
3.3.2  Urinary Tract Infections  
Five variables were collected in respect to urinary infections: temperature spike 
and elevated white cell count, presence of pus cells in the urine, positive urine 
culture and postive urinary catheter tip culture. 
 
For the purposes of this thesis: 
 
Suspected urinary tract infection was the term used when two or more of the 
variables (Table 3.5) were positive.  The temperature spike and elevated white 
cell count were only considered significant if they occurred with other signs or 
symptoms of urinary disease, as opposed to an alternative site of sepsis. 
 
Confirmed urinary tract infection was the term used when a positive culture 
was supported by one or more variables.  
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Table 3.5: Variables supportive of urinary tract infection used in the study 
Variable Description 
Temperature spike Temperature measured above 36.8ºC 
Positive culture growth 
in urine catheter tip  
Laboratory confirmed positive bacterial culture from 
urine catheter tip sample  
Positive culture growth 
in urine  
Laboratory confirmed positive bacterial culture from 
urine sample  
Presence of pus cells in 
urine sample 
Pus cells seen on microscopy by the laboratory in 
the  urine specimen 
Raised white blood 
count 
White blood count of greater than 10 x 10ˆ9/L,  on 
peripheral blood sample as measured by the 
laboratory. 
  
 
Catagorical data analysis of the indicators of urinary tract infection used for the 
purpose of this study, between the intervention and control group, was done 
using  the Mann-Whitney U test.  
 
This showed no statistically significant differences between the intervention and 
control groups for temperature spikes (p=0.54), urine culture (p=0.54) and white 
blood cell count findings (p=0.95) (Table 3.6).  
 
Statistically significant differences were found  between the two groups for pus 
cells (p=0.01), more in the intervention group and positive culture growth from 
catheter tip samples (p=0.04), less in the intervention group. 
 
The intervention group had a higher frequency of pus cells in the urine and the 
control group a higher incidence of positive urine catheter tip culture (Table 3.6).  
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Table 3.6: Urinary tract infection indicators  
Group Temperature 
spikes 
Mean 
[Standard 
Deviation] 
Urine Catheter 
culture growth 
total 
Mean 
[Standard 
Deviation] 
Urine culture 
growth total 
Mean 
[Standard 
Deviation]] 
Pus Cells in 
urine samples 
Mean 
[Standard 
Deviation] 
White Blood 
Count total 
Mean 
[Standard 
Deviation] 
Control 
Group 
3.92 
(3.4) 
3.00 
(4.05) 
3.92 
(3.4) 
2.05 
(5.14) 
13.97 
(5.61) 
Intervention 
Group 
5.33 
(7.16) 
0.41 
(0.79) 
5.33 
(7.16) 
3.67 
(4.75) 
14.32 
(1.65) 
p-level  0.54 
 
0.04 0.54 
 
0.01 0.95 
(Mann-Whitney U Test significant if p < 0.05) 
 
Although there was a statistically significant difference between suspected and 
confirmed urinary tract infections within the intervention group (p=0.03) in favour 
of fewer confirmed infections, there was no statistically signifcant differences in 
confirmed (p=0.08) or suspected (p=0.34) infections between the intervention 
and control groups (Table 3.7). 
 
Table 3.7  Confirmed and suspected urinary tract infections 
 
Suspected 
urinary tract 
infections Mean 
[SD] 
Confirmed 
urinary tract  
infections Mean 
[SD] 
p-value within a 
group Mean [SD] 
Intervention 
Group 
5.25 [6.97] 0.66 [0.89] 0.03 
Control Group 3.08 [3.23] 2.92 [4.10] 0.91 
P-value between 
groups 
0.34 0.08  
ANOVA test significant if p < 0.05 
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3.3.3 Septiceamia  
Three variables were collected in support of a diagnosis of septiceamia, i.e. 
temperature spike, raised white cell count and a positive blood culture. For the 
purposes of this study, septiceamia was deemed to be present when a positive 
blood culture was supported by one other variable (Table 3.8). 
 
Table 3.8 Variables supportive of septiceamia infection  
Variable Description 
Temperature spike Temperature measure above 36.8ºC 
Positive culture growth in blood Laboratory confirmed positive bacterial 
culture from blood sample  
Raised white blood count White blood count of greater than 10 x 
10ˆ9/L,  on peripheral blood sample as 
measured by the laboratory 
 
Catagorical data analysis between the intervention and control group, making 
use of the Mann-Whitney U test, did not differ significantly with respect to any of 
the variables (Table 3.9). 
 
Table 3.9  Sepsis indicators 
Variables Group 
 Temperature  
Spikes  
Mean [SD] 
White Blood 
Count total 
Mean [SD] 
Blood Culture 
Growth 
Mean [SD] 
Control Group 3.92 [3.4] 13.97[5.61] 0.25 [0.62] 
Intervention 
Group 
5.33 [7.16] 14.32[1.65] 2.83 [5.31] 
p-value 0.54 0.95 0.11 
Mann- Whitney U test significant if p < 0.05 
[SD: Standard deviation] 
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When data was analysed for those patients who were diagnosed with 
septiceamia, no statistically significant differences were found within or between 
the intervention and control groups (Table 3.10). 
 
Table 3.10   Prevalence of confirmed and suspected septiceamia 
 
Suspected 
Septiceamia 
(Mean) [SD] 
Confirmed 
Septiceamia 
p-value within a 
group 
Intervention 
Group 
4.25 [5.08] 3.08 [4.14] 0,16 
Control Group 3.25 [3.16] 1.17 [1.70] 0.06 
P-value between 
 Groups 
0.57 0.15 
 
 
ANOVA test significant if p < 0.05 
 
When all the sepsis data was combined for confirmed infections, there was a 
borderline statistically significant difference between the intervention group and 
control groups for respiratory infections (p=0.05), with more confirmed infections 
in the control group. There was no statistically significant difference between the 
groups for either urinary tract infections (p=0.08) or septiceamia (p=0.15), nor 
was there a statistically significant difference  between the two groups when all 
the data was combined (p=79).  (Table 3.11) 
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Table 3.11  Combined  data for confirmed infections 
 
Confirmed 
respiratory 
infection 
Mean [SD] 
Confirmed 
urinary tract 
infection 
Mean [SD] 
Septiceamia 
Mean [SD] 
Total 
Intervention 
Group 
0.08 [0.28] 0.66 [0.89] 3.08 [4.14] 3.50 [4.76] 
Control Group 1.58 [2.47] 2.92 [4.10] 1.17 [1.70] 4.08 [6.02] 
p- value 0.05 0.08 0.15 0.79 
ANOVA test significant if p < 0.05 
 
3.3.4 Ventilation days 
For the purposes of this study, ventilation days were defined as total days a 
patient spent on a ventilator during the ICU stay. A day was defined as being 
from 06.00am to 05.59am or part thereof, and was taken from the ICU clinical 
chart on which all ventilation parameters were recorded hourly by the ICU nurse 
in charge of the patient. No significant difference was found between the 
intervention and control groups for number of days spent on a ventilator (p=0.78). 
The intervention group spent a mean of 11.08 days and the control group a mean 
of 12.67 days on the ventilator  (Table 3.12). 
 
Table 3.12: Ventilator Days  
Group 
Ventilator Days 
Total Mean 
Ventilator Days 
Total SD 
P-level 
(significant p<0.05) 
Control Group 11.08 14.42 
Intervention 
Group 
12.67 13.17 
 
0.78 
(not significant) 
 
SD : Standard Deviation 
 (Mann-Whitney  U test, p = 0.78) 
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3.3.5 Length of Stay in the Intensive Care Unit 
For the purpose of this study, length of stay in ICU was defined as from the day 
of admission to ICU as day one, and to the day of discharge from ICU as the last 
day in ICU. A day was defined as being from 06h00am until 05h59am, or any 
part thereof, and calculated from the ICU clinical chart.  No significant differences 
were found between the intervention and control groups regarding days spent in 
the ICU.  The intervention group spent a mean of 13.6 days and the control group 
spent a mean of 16.7 days in ICU. (Table 3.13, p=0.61)  
 
Table 3.13 :  Days spent in  Intensive Care Unit  
Group 
Days in ICU 
Total Mean 
Days in ICU 
Total SD 
P-level 
(significant p<0.05) 
Control Group 13.6 4.1 
Intervention 
Group 
16.7 4.1 
 
0.61 
(not significant) 
 
SD: Standard Deviation 
(Mann- Whitney U test, p = 0.61) 
 
3.4 SAFETY AND ADVERSE EVENTS 
There were no adverse events documented in the intervention group and no 
patient died or withdrew from the study prematurely. No adverse events led to 
discontinuation or reduction in the enteral Intestamin® supplement in this group 
and all patients were able to tolerate the enteral supplement for the duration of 
the study. 
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Study motivation and findings 
The motivation for this study arose out of the concept that certain nutritional 
supplements have expected benefits in critically ill patients because of their role 
in the immune response of the body to stress states, as the discussion in the 
preceding chapters has shown.5 7 This is a particularly attractive concept, when 
the role of immune dysregulation in critical illness is considered. The results of 
this study have supported this benefit in some, but not all respects. The study 
has shown a statistically significant benefit in the patients, who received the 
immune supplement, only in the incidence of respiratory infections and the 
positive culture rates for tracheal aspirates and urinary catheter tip cultures, but 
has failed to show statistically significant differences between the intervention 
and control groups for other types of sepsis or for the ventilation time and time 
spent in ICU which were broadly considered to represent surrogate markers of 
the disease course. There were, in addition, statistically significant differences 
between the two groups with respect to the presence of pus cells in the sputum 
and urine which were higher in the intervention group and showed an inverse 
relationship with positive cultures. It is difficult to interpret this clinically and in 
isolation, but it may support a difference in the systemic immune response to 
infection between the two groups. Because pus cells are a marker for 
inflammation or infection, in the absence of a positive culture growth, it is 
tempting to speculate that the intervention group may be demonstrating an 
improved immune response.99 Further study would be needed to clarify the 
significance of this relationship .  
 
The failure to show improvement in overall sepsis rates, ventilation time  and ICU 
stay is disappointing, but there are several factors in the design and 
implementation of the study which may have influenced these outcomes. The 
results, therefore, remain encouraging in supporting the role of early 
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immunonutrition supplements in this patient group. Although anecdotal, and open 
to the bias of an open label study, the clinicians involved in the trial felt that their 
patients made better progress in the intervention group and they were 
subsequently keen to implement more aggressive nutritional strategies in the 
future.  
 
Study limitations 
In further considering the significance of the results, it is necessary to look 
critically at some of the limitations of the study which may have influenced the 
results and the likelihood of bias affecting the outcome. 
 
As has been stated previously, this study must be considered as a pilot study 
only, not least because of the small numbers recruited and analysed. It is widely 
recognized that studies of enteral and parenteral nutrition require large numbers 
of patients to reach statistical significance because of the difficulties in studying 
critically ill patients in the ICU, the heterogeneous population of patients and the 
variables involved in disease-specific enteral and parenteral nutrition.. A large 
study group was not practicable in this study, because of limitations imposed by 
the size of the ICU in which the study was performed, the rate at which suitable 
patients presented to the unit and a fixed time frame for the study. Under these 
circumstances, the fact that any statistically significant differences were found, 
could be granted additional significance in support of the concept being tested. 
The numbers studied were insufficient to provide the statistical power needed 
and more robust conclusions could be expected from a much larger study group. 
 
Additional bias may also be evident in the study design, in that it was open label, 
with the controls being identified and matched retrospectively. This was 
necessary again to maximize the available data from the intervention group. Had 
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both groups been studied prospectively in the same time frame, the study 
population would have been halved, with consequent exaggeration of the sample 
size limitations already discussed. So, to maximize patient numbers, the design 
was adapted. The strongest data however is derived from parallel double blinded 
studies where bias, related to uncontrolled differences between the two 
population groups, can be minimized and observer bias is also controlled.5 10 If, 
for example, there were significant differences between the two groups in terms 
of treatment protocols, this would have affected the results. Intensive care is a 
dynamic specialty, and although protocols in this ICU have been standardized, in 
reality practices may change over a 23 month period, the time period which 
separated the controls from the intervention groups in this study. Bias, as result 
of this time lapse,  cannot be ruled out . 
 
The patients were chosen and matched according to disease-severity, based on 
APACHE scoring, which has been the basis of many other trials using ICU 
patients and correlates with outcome. 5 60 Despite this, the patients still manifest 
clinical heterogeneity. The patients in ICU are there because of the level of care 
they require, but are drawn from many subspecialities with associated 
comorbidities and pre-existing disease which will also influence the course of 
their illness. Thus medical patients may well behave differently from surgical 
patients, and trauma patients differently from elective patients, despite the illness 
severity scoring equally on the APACHE at the entry into the ICU.  
 
In this area on the east coast of South Africa there is a high prevalence of HIV 
and AIDS among the patient population treated, indeed the highest in the 
country. 100 101 The prevalence of the infection is plateauing out according to 
epidemiological surveys, but between 2002 (first control patient in the study) and 
2003 (last intervention patient in the study) there was a change in the prevalence 
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in Kwa Zulu Natal according to CDC statistics of up to 2%.100 101 In such a small 
patient cohort, this could easily equate to a difference in prevalence of HIV 
positive patients in the two groups sufficient to influence the outcome 
parameters.  
  
The issue of the effect of HIV status on the outcome in ICU is an interesting and 
complex one. In 1997 Bhagwanjee et al published a paper in the BMJ on the 
effect of HIV status on the outcome of patients admitted to the ICU.102  The 
authors studied over 400 patients admitted to a large academic hospital ICU in 
Durban. They found no difference in the length of hospital or ICU stay or in 
mortality between HIV positive and negative patients, but they did find statistically 
significant differences between the two groups in morbidity, including a higher 
incidence of septic shock in HIV positive patients.102 The two groups were not 
significantly different in respect to the APACHE scores, and therefore this will not 
differentiate between HIV positive and negative patients . More of the HIV 
positive patients came from orthopaedic and obstetric referrals, rather than 
medical referrals, which would again  impact on the emergency trauma patient 
population  and introduce possible bias in this group. There were no patients with 
apparently advanced immunosuppression and AIDS, the presence of which 
would be expected to influence the outcomes further and perhaps differently. So 
is it possible that a high HIV or AIDS rate detracted from the significance of the 
results in this study. There is no way of knowing, as this was not a parameter 
collected or indeed known in the majority of cases. However, bias associated 
with this factor cannot be excluded. 
 
Upon reflection, the outcome measurements in this study need to be 
reconsidered. Using infection indicators as a single prognostic indicator in 
patients with multiple medical problems is simplistic and may not give the most 
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accurate indication of prognosis and outcome. More integrated scoring systems 
would offer a more accurate assessment.  In 2008, Beale et al5 published a study 
which investigated the effect of early enteral supplementation with Intestamin® 
on outcome in critically ill patients and they chose the outcome parameter of a 
compound score of sequential organ failure assessment, the SOFA score.  The 
SOFA score is a score of six organ dysfunctions and can be applied sequentially 
in an ICU environment to chart the progress and assess prognosis. Both the 
mean, highest and change scores in SOFA scores are used as predictors of 
outcome in ICU and have shown to correlate well with morbidity and mortality. In 
the study by Beale the aim was to enroll 344 patients, but after the interim 
analysis of the first 50 patients the study was stopped. The results were 
overwhelmingly positive in favour of the Intestamin® group in terms of the 
improved SOFA scores, and  continuing to enroll patients as placebo could not 
be justified ethically in the light of this finding. If a compound scoring system had 
been used in our study, it is tempting to speculate that the results may have been 
more strongly significant. Even with the strongly positive findings in Beales group, 
there was no difference between the groups for ICU/Hospital stay or infections, 
which mirrors the findings in  our pilot study, but does not detract from the 
strongly positive benefits that they demonstrated on the SOFA scoring. Again this 
would suggest that the use of the length of ICU or hospital stay and even 
infection rates, as outcome parameters, may not be sensitive enough in 
identifying clinical benefit from Intestamin in a trial setting and why the endpoints 
in our pilot study were only partially met. 5  
 
Advantages of Intestamin® 
One of the advantages of Intestamin® is the small volume containing high doses 
of key nutrients. Thus the full volume of the supplement can be administered 
much sooner after admission into ICU. This is not possible with the old 
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generation enteral feeds. The manufacturer’s recommendation is for a full 500mls 
to be administered from the first day of ICU stay and for 5 days thereafter. As this 
supplement was new at the time of our study, and the experience with the feed 
tolerance uncertain, the study aimed at introducing the full Intestamin® volume 
by the second ICU day. This was achieved in practice on day 1, the patients 
receiving between 105 and 483 mls of Intestamin®, but by day 2  and thereafter, 
all patients in the intervention group received 500 mls. At the end of 5 days of 
Intestamin®, the patients in the intervention group had received a total dose of 
Intestamin® of between 2105 and 2483 mls with a mean of 2294 mls,  which is a 
mean short fall in the intended total Intestamin® dose of  206 mls. Whether this 
impacted negatively on the benefits is difficult to judge. Faster run rates and 
higher total volumes of the Intestamin® may achieve higher benefits. In the study 
by Beale et al, with strongly positive results in favour of the Intestamin® treated 
group, Intestamin® was continued for a 10 day period. Although 5 days is 
recommended as the Intestamin® supplement course by the manufacturers, the 
results from Beale et al suggest that the optimum duration of Intestamin® 
supplementation for the maximum benefits still needs to be determined. 
 
Heterogenous population in ICU 
A final consideration in interpreting the results of this study must include the fact 
that Intestamin®, while having been developed to respond to many of the needs 
of an early enteral nutritional supplement, in respect of the feed volume and 
content, may not necessarily represent the best formulation for all patient groups. 
From the preceding discussion of the metabolic responses in critically stressed 
patients, it is clear that not all patients undergo the same changes in response to 
stress and this brings us back to the heterogenous population in the ICU. 
Different patients have different rates of nutrient depletion such as glutamine and 
antioxidants. Therefore different patients may need different doses in their 
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replacement. For example burn patients are recognised as having greater losses 
than those that occur in other types of  trauma.58 Error! Bookmark not defined. If this is 
considered, then it is clear that a generic supplement across all patient groups 
cannot possibly meet each patients need optimally, but rather will represent the 
best available compromise. Beale et al 5  measured the serum levels of several of 
the supplement constituents in the patient population receiving Intestamin® and 
in the controls and showed normalization of these parameters in the Intestamin® 
group, consistent with Intestamin® being a successful product for the treatment 
of these deficiencies, compared to the control group. This type of monitoring may 
allow the clinician to individualize the supplement to the patient’s needs more 
efficiently and to allow for a range of runing rates, total duration or even a range 
of products to be chosen in the future. 
 
This conclusion naturally relies on the assumption that the levels of these 
supplements, deemed normal in a normal population, reflect the correct levels for 
the increased needs in metabolic stress. The US Food and Nutrition Board 
defined NOAEL and LOAEL for antioxidant supplements on the levels associated 
with no adverse effects in a normal population.64 These do not necessarily 
correlate with the levels needed in altered metabolic states, and again it is 
evident that there needs to be more clarification through further research, as the 
relative composition of these immunosupplements may well affect their potential 
benefit and may need to be disease-specific. 
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Tolerance of supplement 
The use of nasojejunal feeding in this study was associated with good tolerance 
of the Intestamin® supplement in the intervention group. This is perhaps not 
surprising in that nasojejunal feeding is recognised as a strategy to overcome 
enteral tolerance problems in this patient population.81 It could be argued that 
nasojejunal feeding is the preferred route of enteral nutrition in the critically ill ICU 
patient especially in the early stages of enteral feeding.  103 104 105 
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5.1 CONCLUSIONS AND RECOMMENDATIONS 
 
This pilot study confirmed the tolerability of the supplement 
Intestamin®,administered to a population of critically ICU patients via the 
nasojejenal route and in combination with either TPN or enteral nutrition. 
 
Furthermore, the use of Intestamin® early in this group was associated with 
measurable benefits in the rate of respiratory infection and positive sputum and 
urinary catheter tip cultures, despite results which showed no benefit in the rates 
of urinary infections , septicaemia , hospital ventilation and ICU days. This can be 
seen as a possible indication that Intestamin® can be of benefit in decreasing 
nosocomial respiratory infections, specifically, in patients on ventilatory support. 
 
 Although Intestamin® supplementation did not result in conclusive benefits in the 
other end points studied in this intervention group, larger prospective studies with 
broader end points are recommended to clarify the remaining issues. 
 
5.2 RECOMMENDATIONS 
 
The use of Intestamin® as a supplemental feed to TPN or enteral nutrition may 
be beneficial by improving the outcome of nosocomial infections in critically ill 
patients in an ICU setting. 
 
Further investigations are needed, using this supplement, in a larger group of 
patients over a longer period of time, with alternative outcomes and controlling for 
patient variables in order to identify more accurately those patient groups most 
likely to benefit, and also to better understand the scope of the benefits. It is 
strongly suggested that different population groups  are  studied separately in 
formalized clinical trials. 
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Generating the APACHE II Score 
Overview:  
The APACHE II score is a general measure of disease severity based on current physiologic 
measurements age and previous health condition.  The score can help in the assessment of 
patients to determine the level and degree of diagnostic and therapeutic intervention. 
 Components: 
(1) acute physiology score (APS) 
(2) age points 
(3) chronic health points 
 Data collection: 
• The data for the acute physiology is collected during the initial 24 hour period after ICU 
admission. 
• The worst (most deranged) physiologic value is selected for grading. 
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Acute Physiology Score (APS) 
Parameter Finding Points -1 1 2 3 4 5 
rectal temp in C° 
>= 41 +4       
39-40.9 +3       
38.5-38.9 +1       
36-38.4 0       
34-35.9 +1       
32-33.9 +2       
30-31.9 +3       
<= 29.9 +4       
mean arterial 
pressure mm Hg 
>= 160 +4       
130-159 +3       
110-129 +2       
70-109 0       
50-69 +2       
<= 49 +4       
heart rate in 
beats/minute 
>= 180 +4       
140-179 +3       
110-139 +2       
70-109 0       
55-69 +2       
40-54 +3       
<= 39 +4       
respiratory rate in 
breaths/min 
>=50 +4       
35-49 +3       
25-34 +1       
12-24 0       
10-11 +1       
6-9 +2       
<= 5 +4       
oxygenation 
A-aDO2 >= 500 and FIO2 >= 0.5 +4       
A-aDO2 350-499 and FIO2 >= 0.5 +3       
A-aDO2 200-349 and FIO2 >= 0.5 +2       
A-aDO2 < 200 and FIO2 >= 0.5 0       
PaO2 > 70 and FIO2 < 0.5 0       
PaO2 61-70 and FIO2 < 0.5 +1       
PaO2 55-60 and FIO2 < 0.5 +3       
PaO2 < 55 and FIO2 < 0.5 +4       
arterial pH 
>= 7.7 +4       
7.6-7.69 +3       
7.5-7.59 +1       
7.33-7.49 0       
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Parameter Finding Points -1 1 2 3 4 5 
7.25-7.32 +2       
7.15-7.24 +3       
< 7.15 +4       
serum sodium 
>= 180 +4       
160-179 +3       
155-159 +2       
150-154 +1       
130-149 0       
120-129 +2       
111-119 +3       
<= 110 +4       
serum potassium 
>= 7.0 +4       
6.0-6.9 +3       
5.5-5.9 +1       
3.5-5.4 0       
3.0-3.4 +1       
2.5-2.9 +2       
< 2.5 +4       
serum creatinine 
in mg/dL 
>= 3.5 and not acute renal failure +4       
2.0-3.4 and not acute renal failure +3       
1.5-1.9 and not acute renal failure +2       
0.6-1.4 and not acute renal failure 0       
< 0.6 and not acute renal failure +2       
>= 3.5 and acute renal failure +8       
2.0-3.4 and acute renal failure +6       
1.5-1.9 and acute renal failure +4       
0.6-1.4 and acute renal failure 0       
< 0.6 and acute renal failure +4       
hematocrit in 
percent 
>= 60 +4       
50-59.9 +2       
46-49.9 +1       
30-45.9 0       
20-29.9 +2       
< 20 +4       
WBC count in 
thousands 
>= 40 +4       
20-39.9 +2       
15-19.9 +1       
3-14.9 0       
1-2.9 +2       
< 1 +4       
Glasgow Coma 
Score 
  15 -        
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 where: 
• The score for serum creatinine is doubled if the patient has acute renal failure. 
• mean arterial pressure = ((systolic blood pressure)+ (2 * (diastolic pressure))) / 2 
 If no blood gas data is available then the serum bicarbonate can be used ( assume in place of 
the arterial pH):  
Parameter Finding Points -1 1 2 3 4 5 
serum bicarbonate 
in mmol/L 
>= 52.0 +4       
41.0 – 51.9 +3       
32.0 – 40.9 +1       
22.0 – 31.9 0       
18.0 – 21.9 +2       
15.0 – 17.9 +3       
< 15.0 +4       
        
Age Points 
Age Points 
<= 44 0 
45-54 2 
55-64 3 
65-74 5 
>= 75 6 
 
Chronic Health Points 
Operative Status Health Status Points 
Non-operative patient 
history of severe organ insufficiency OR immune compromised 5 
no history of severe organ insufficiency AND immune 
competent 
0 
Emergency postoperative 
patient 
history of severe organ insufficiency OR immune compromised 5 
no history of severe organ insufficiency AND immune 
competent 
0 
Elective postoperative patient 
history of severe organ insufficiency OR immune compromised 2 
no history of severe organ insufficiency AND immune 
competent 
0 
 where: 
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 organ insufficiency or immune compromised state must have preceded the current 
admission 
 
 immune compromised if:  
(1)  receiving therapy reducing host defenses (immune suppression chemotherapy 
radiation therapy long term steroid use high dose steroid therapy) or  
(2)  has a disease severe enough to interfere with immune function such as 
malignant lymphoma leukemia or AIDS 
 
 liver insufficiency if:  
(1)  biopsy proven cirrhosis  
(2)  portal hypertension  
(3)  episodes of upper GI bleeding due to portal hypertension (4) prior episodes of 
hepatic failure coma or encephalopathy 
 
 cardiovascular insufficiency if:  
(1)  New York Heart Association Class IV 
 
 respiratory insufficiency if:  
(1)  severe exercise restriction due to chronic restrictive obstructive or vascular 
disease; 
(2)  documented chronic hypoxia hypercapnia secondary polycythemia severe 
pulmonary hypertension; and 
(3)  respirator dependency 
 
 renal insufficiency if:  
(1) on chronic dialysis 
  
APACHE II SCORE 
 
Apache Score  =  (acute physiology score) + (age points) + (chronic health points) 
 Interpretation: 
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 minimum score:   0  
 maximum score:   71 
 An increasing score is associated with an increasing risk of hospital death. 
  
References: 
Knaus WA Draper EA et al. APACHE II: A severity of disease classification system. Critical 
Care Medicine. 1985; 13  
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Computing the Predicted Death Rate for Acutely Ill Patients with 
APACHE II 
Overview:  
From the APACHE II score and knowledge of primary clinical diagnoses an estimated risk of 
death in the hospital can be calculated.  
R = estimated risk of hospital death  
ln  (R / (1 - R)) = (-3.517) + (0.146 * (APACHE II score)) + (0.603 if post-emergency 
surgery 0 if not) + (diagnostic category weight) 
Diagnostic Category - Nonoperative 
Group Disorder Weight 
respiratory failure or 
insufficiency 
asthma or allergy -2.108 
COPD -0.367 
pulmonary edema noncardiogenic -0.251 
post-respiratory arrest -0.168 
aspiration -0.142 
poisoning or toxic -0.142 
pulmonary embolus -0.128 
infection 0 
neoplasm 0.891 
cardiovascular failure or 
insufficiency 
hypertension -1.798 
rhythm disturbance -1.368 
congestive heart failure -0.424 
hemorrhagic shock or hypovolemia 0.493 
coronary artery disease -0.191 
sepsis 0.113 
postcardiac arrest 0.393 
cardiogenic shock -0.259 
dissecting aortic aneurysm 0.731 
trauma 
multiple trauma -1.228 
head trauma -0.517 
neurologic 
seizure disorder -0.584 
ICH/SDH/SAH 0.723 
other drug overdose -3.353 
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Group Disorder Weight 
diabetic ketoacidosis -1.507 
GI bleeding 0.334 
vital organ affected 
metabolic or renal -0.885 
respiratory -0.890 
neurologic -0.759 
cardiovascular 0.470 
gastrointestinal 0.501 
  
Diagnostic Category - Operative  
Group Disorder Weight 
Operation 
multiple trauma -1.684 
chronic cardiovascular disease -1.376 
peripheral vascular disease -1.315 
heart valve surgery -1.261 
craniotomy for neoplasm -1.245 
renal surgery for neoplasm -1.204 
renal transplant -1.042 
head trauma -0.955 
thoracic surgery for neoplasm -0.802 
craniotomy for ICH/SDH/SAH -0.788 
laminectomy or other spinal cord surgery -0.699 
hemorrhagic shock -0.682 
GI bleeding -0.617 
GI surgery for neoplasm -0.248 
respiratory insufficiency after surgery -0.140 
GI perforation or obstruction 0.060 
Postoperative complications 
sepsis 0.113 
Post cardiac arrest 0.393 
Post respiratory arrest -0.168 
NOS 
neurologic -1.150 
cardiovascular -0.797 
respiratory -0.610 
gastrointestinal -0.613 
metabolic renal -0.196 
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INFORMATION AND INFORMED CONSENT DOCUMENT 
TITLE OF THE RESEARCH PROJECT:  
A STUDY OF THE EFFECT OF INTESTAMIN® ADMINISTRATION TO CRITICALLY 
ILL PATIENTS ON THE PREVALENCE OF INFECTION, VENTILATION 
REQUIREMENTS AND DURATION OF HOSPITAL STAY. 
 
REFERENCE NUMBER:   ……………………………….……………………. 
PRINCIPAL INVESTIGATOR:  Mrs  HS VAN NIEKERK, RD(SA)ADE, 
DR  G KELLING,  SPECIALIST SURGEON,  
DR  P VAN ROOYEN, SPECIALIST SURGEON  
 
(hereinafter referred to as “Investigators”) 
 
ADDRESS:  PO BOX 41357,  
 RICHARDS BAY 
 3900 
 
DECLARATION BY OR ON BEHALF OF PARTICIPANT: 
I, the undersigned,             BARBARA               MOORE                   . (name) 
[ID No: 5708300270082 in my capacity as THE HOSPITAL MANAGER of the patients 
as listed in Annexure “A” 
A. HEREBY CONFIRM AS FOLLOWS: 
1. I was invited to participate in the abovementioned research project which is 
being undertaken by the Investigators in collaboration with the Department of 
Human Nutrition, Faculty of Health Sciences, Stellenbosch University for the 
purpose of completing a Masters Degree in Human Nutrition for Mrs. HS van 
Niekerk. 
2. The following aspects have been explained to me: 
2.1 Aim:    The purpose of this study is to determine the effect of Intestamin® 
administration to critically ill patients on the prevalence of infection, ventilation 
requirements and duration of hospital stay determining if Intestamin® decrease 
nosocomial infection (lung, urine and linesepsis) rate in the critically ill, 
ventilation days in the critically ill, and the length of stay in ICU. The hypothesis 
of this study then is to determine if Intestamin® administered to the critically ill 
patients will have beneficial effects on the prevalence of infection, ventilation 
requirements and duration of ICU stay. 
2.2 Procedures:  The study design covers a retrospective, case control, analytical 
study of patients that have been admitted to ICU (The Bay Hospital) and treated 
with Intestamin ® during June 2003 until November 2003 and a literature 
overview. These results will be compared with patients (control group) with 
similar conditions that were admitted in ICU (The Bay Hospital) during the period 
from January 2002 until end off May 2003 (comparative period), and which were 
not treated with Intestamin®. These two groups could be compared as there was 
no protocol change in the management off patients in ICU during the mentioned 
periods. The diagnostic criteria and treatment procedures would stay the same, 
except for the use off Intestamin ® in the intervention group. 
2.3 Risks:  As the study only compares and is retrospective in terms of 
patients treated with Intestamin ® and those not treated with Intestamin ®, also 
considering that Intestamin ® was only introduced in June 2003, no risk exists. 
2.5 Benefits:    The preliminary results of the study indicate that there could be 
clear benefits in terms of the effects on the prevalence of infection, ventilation 
requirements and duration of ICU stay.  
2.6 Confidentiality:  The information collected will be treated as confidential, it will 
be included in a thesis, and publication in a professional journal, without 
disclosing the identity of the patients. 
3. The information above was explained to me by a representative of the 
Investigators in English and I am in command of this language. I was given the 
opportunity to ask questions and all these questions were answered 
satisfactorily. 
4. No pressure was exerted on me to consent to participation and I understand(s) 
that I may withdraw at any stage without any penalization. 
B. I HEREBY BY THE AUTHORTY VESTED IN ME AS THE BAY HOSPITAL 
MANAGER GIVE CONSENT THAT THE LISTED ICU PATIENT(S) DESEASE 
MANAGEMENT INFORMATION AND ALL RELEVANT INFORMATION 
REQUIRED FOR THE ABOVEMENTIONED STUDY BE USED 
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IMPORTANT MESSAGE TO PATIENT/*REPRESENTATIVE OF PARTICIPANT: 
 
Dear participant, 
Thank you for THE BAY HOSPITALS participation in this study.  Should, at any time 
during the study, 
• an emergency arise as a result of the research, or 
• you require any further information with regard to the study, kindly contact: 
 Mrs HS van Niekerk at telephone number 083 460 7591. 
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The Bay Hospital ICU Feeding protocol 
Day 
count 
Patient nutritional 
needs 
(25kcal/kg/day) 
Total Parental 
Nutrition (TPN) 
running rate / hour 
Hours 
Intestamin 
running rate 
/ hour 
Standard Enteral 
feed running rate / 
hour (disease 
specific) 
Nasogastric 
aspirate (ml) 
after no enteral 
feed for 1 hour 
1 
Patient specific Disease specific 1 10  Nil 
 94 4 15 0 Nil 
 80 8 22 0 Nil 
 60 12 33 30 Nil 
 50 16 50 50 Nil 
  24   Nil 
After 4 hours of enteral feeding, stop feed for 1 hour and do enteral nasogastric asparate. If Aspirate less than 50% of total 
enteral intake then increase with 50%, if aspirate equal the amount enteral intake keep at the same running rate, if 
aspirate > 50% of total enteral intake then decrease running rate with 50 %. 
2 
  1    
  4    
  8    
  12    
  16    
  24    
 
3 
  1    
  4    
  8    
  12    
  16    
  24    
 
4 
  1    
  4    
  8    
  12    
  16    
  24    
 
5 
  1    
  4    
  8    
  12    
  16    
  24    
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